CA2631537A1 - Dentifrice composition free of abrasive material - Google Patents
Dentifrice composition free of abrasive material Download PDFInfo
- Publication number
- CA2631537A1 CA2631537A1 CA002631537A CA2631537A CA2631537A1 CA 2631537 A1 CA2631537 A1 CA 2631537A1 CA 002631537 A CA002631537 A CA 002631537A CA 2631537 A CA2631537 A CA 2631537A CA 2631537 A1 CA2631537 A1 CA 2631537A1
- Authority
- CA
- Canada
- Prior art keywords
- zinc
- dentifrice composition
- composition
- agents
- mixtures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 133
- 239000000551 dentifrice Substances 0.000 title claims abstract description 37
- 239000003082 abrasive agent Substances 0.000 title claims abstract description 29
- 239000000463 material Substances 0.000 claims abstract description 59
- -1 phytic acid compound Chemical class 0.000 claims abstract description 29
- 239000004927 clay Substances 0.000 claims abstract description 20
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 18
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940068041 phytic acid Drugs 0.000 claims abstract description 12
- 239000000467 phytic acid Substances 0.000 claims abstract description 12
- 239000002798 polar solvent Substances 0.000 claims abstract description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 38
- 239000011701 zinc Substances 0.000 claims description 38
- 229910052725 zinc Inorganic materials 0.000 claims description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000000377 silicon dioxide Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000011230 binding agent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims description 10
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 9
- 230000002272 anti-calculus Effects 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 230000002882 anti-plaque Effects 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 8
- 229920000388 Polyphosphate Chemical class 0.000 claims description 7
- 239000004599 antimicrobial Substances 0.000 claims description 7
- UOURRHZRLGCVDA-UHFFFAOYSA-D pentazinc;dicarbonate;hexahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2].[O-]C([O-])=O.[O-]C([O-])=O UOURRHZRLGCVDA-UHFFFAOYSA-D 0.000 claims description 7
- 239000001205 polyphosphate Chemical class 0.000 claims description 7
- 235000011176 polyphosphates Nutrition 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 229920006318 anionic polymer Polymers 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 230000008719 thickening Effects 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 239000007844 bleaching agent Substances 0.000 claims description 4
- SUCKQWWOYOOODR-UHFFFAOYSA-K copper;zinc;carbonate;hydroxide Chemical compound [OH-].[Cu+2].[Zn+2].[O-]C([O-])=O SUCKQWWOYOOODR-UHFFFAOYSA-K 0.000 claims description 4
- 239000000391 magnesium silicate Substances 0.000 claims description 4
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 4
- 235000019792 magnesium silicate Nutrition 0.000 claims description 4
- 229960003500 triclosan Drugs 0.000 claims description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229920001206 natural gum Polymers 0.000 claims description 3
- 229910052604 silicate mineral Inorganic materials 0.000 claims description 3
- 230000001680 brushing effect Effects 0.000 claims description 2
- 229910052615 phyllosilicate Inorganic materials 0.000 claims description 2
- MQWLIFWNJWLDCI-UHFFFAOYSA-L zinc;carbonate;hydrate Chemical compound O.[Zn+2].[O-]C([O-])=O MQWLIFWNJWLDCI-UHFFFAOYSA-L 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims 1
- 230000008901 benefit Effects 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 14
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000008375 oral care agent Substances 0.000 description 11
- 229910052783 alkali metal Inorganic materials 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 7
- 239000011775 sodium fluoride Substances 0.000 description 7
- 235000013024 sodium fluoride Nutrition 0.000 description 7
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 7
- 239000000606 toothpaste Substances 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- 239000011667 zinc carbonate Substances 0.000 description 7
- 235000004416 zinc carbonate Nutrition 0.000 description 7
- 229910000010 zinc carbonate Inorganic materials 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920000098 polyolefin Polymers 0.000 description 6
- 229960002799 stannous fluoride Drugs 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 230000000675 anti-caries Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 229940008099 dimethicone Drugs 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 238000000518 rheometry Methods 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 229940083982 sodium phytate Drugs 0.000 description 5
- 229920001285 xanthan gum Polymers 0.000 description 5
- 239000000230 xanthan gum Substances 0.000 description 5
- 235000010493 xanthan gum Nutrition 0.000 description 5
- 229940082509 xanthan gum Drugs 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 4
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000871495 Heeria argentea Species 0.000 description 3
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001336 alkenes Chemical group 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004673 fluoride salts Chemical class 0.000 description 3
- 229940091249 fluoride supplement Drugs 0.000 description 3
- 229910021485 fumed silica Inorganic materials 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical class [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- GPXCJKUXBIGASD-UHFFFAOYSA-N 1-phosphonobutane-1,2,4-tricarboxylic acid Chemical compound OC(=O)CCC(C(O)=O)C(C(O)=O)P(O)(O)=O GPXCJKUXBIGASD-UHFFFAOYSA-N 0.000 description 2
- YFVBASFBIJFBAI-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 YFVBASFBIJFBAI-UHFFFAOYSA-M 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- ANAAMBRRWOGKGU-UHFFFAOYSA-M 4-ethyl-1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(CC)C=C1 ANAAMBRRWOGKGU-UHFFFAOYSA-M 0.000 description 2
- FHEHIXJLCWUPCZ-UHFFFAOYSA-N 4-prop-2-enylbenzene-1,2-diol Chemical compound OC1=CC=C(CC=C)C=C1O FHEHIXJLCWUPCZ-UHFFFAOYSA-N 0.000 description 2
- FEEPYEXHXJWMAX-UHFFFAOYSA-N 6-benzyl-2,6-diazaspiro[3.4]octane Chemical compound C=1C=CC=CC=1CN(C1)CCC21CNC2 FEEPYEXHXJWMAX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- IWEDUKDKQUXPLH-NFJZTGFVSA-L [Mg++].OP(O)(=O)O[C@H]1[C@@H](OP(O)(O)=O)C(OP(O)([O-])=O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)C1OP(O)([O-])=O Chemical compound [Mg++].OP(O)(=O)O[C@H]1[C@@H](OP(O)(O)=O)C(OP(O)([O-])=O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)C1OP(O)([O-])=O IWEDUKDKQUXPLH-NFJZTGFVSA-L 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910001515 alkali metal fluoride Inorganic materials 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003610 anti-gingivitis Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 description 2
- 235000019402 calcium peroxide Nutrition 0.000 description 2
- 229940078916 carbamide peroxide Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- JJLJMEJHUUYSSY-UHFFFAOYSA-L copper(II) hydroxide Inorganic materials [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 235000019820 disodium diphosphate Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- WPEXVRDUEAJUGY-UHFFFAOYSA-B hexacalcium;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OC1C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C(OP([O-])([O-])=O)C1OP([O-])([O-])=O WPEXVRDUEAJUGY-UHFFFAOYSA-B 0.000 description 2
- 229940005740 hexametaphosphate Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- 230000003212 lipotrophic effect Effects 0.000 description 2
- 239000003912 lipotropic agent Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- JTDPJYXDDYUJBS-UHFFFAOYSA-N quinoline-2-carbohydrazide Chemical compound C1=CC=CC2=NC(C(=O)NN)=CC=C21 JTDPJYXDDYUJBS-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000019832 sodium triphosphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- ZSUXOVNWDZTCFN-UHFFFAOYSA-L tin(ii) bromide Chemical compound Br[Sn]Br ZSUXOVNWDZTCFN-UHFFFAOYSA-L 0.000 description 2
- JTDNNCYXCFHBGG-UHFFFAOYSA-L tin(ii) iodide Chemical compound I[Sn]I JTDNNCYXCFHBGG-UHFFFAOYSA-L 0.000 description 2
- 229940001496 tribasic sodium phosphate Drugs 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- DIYWRNLYKJKHAM-MDOVXXIYSA-N (-)-cubebin Chemical compound C1=C2OCOC2=CC(C[C@@H]2[C@@H](CC=3C=C4OCOC4=CC=3)CO[C@@H]2O)=C1 DIYWRNLYKJKHAM-MDOVXXIYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- BYOBJKVGOIXVED-UHFFFAOYSA-N (2-phosphonoazepan-2-yl)phosphonic acid Chemical compound OP(O)(=O)C1(P(O)(O)=O)CCCCCN1 BYOBJKVGOIXVED-UHFFFAOYSA-N 0.000 description 1
- GDRWQOJIKFWLOC-UHFFFAOYSA-N (2-phosphonopyrrolidin-2-yl)phosphonic acid Chemical compound OP(O)(=O)C1(P(O)(O)=O)CCCN1 GDRWQOJIKFWLOC-UHFFFAOYSA-N 0.000 description 1
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 1
- CKUJRAYMVVJDMG-IYEMJOQQSA-L (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;tin(2+) Chemical compound [Sn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CKUJRAYMVVJDMG-IYEMJOQQSA-L 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- FZKWRPSUNUOXKJ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrate Chemical compound O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O FZKWRPSUNUOXKJ-CVHRZJFOSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- JLPAMKUIIFHLBH-UHFFFAOYSA-N 1,2-dihydroxypropane-1-sulfonic acid Chemical compound CC(O)C(O)S(O)(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-N 0.000 description 1
- AHJNNVQDCGWVNU-UHFFFAOYSA-N 1,3,2$l^{2}-dioxastannolane Chemical compound C1CO[Sn]O1 AHJNNVQDCGWVNU-UHFFFAOYSA-N 0.000 description 1
- OQBLGYCUQGDOOR-UHFFFAOYSA-L 1,3,2$l^{2}-dioxastannolane-4,5-dione Chemical compound O=C1O[Sn]OC1=O OQBLGYCUQGDOOR-UHFFFAOYSA-L 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- RWMSXNCJNSILON-UHFFFAOYSA-N 2-[4-(2-propylpentyl)piperidin-1-yl]ethanol Chemical compound CCCC(CCC)CC1CCN(CCO)CC1 RWMSXNCJNSILON-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- UDFNOXIWFOPREQ-UHFFFAOYSA-N 2-phosphonopropane-1,1,1-tricarboxylic acid Chemical compound OP(=O)(O)C(C)C(C(O)=O)(C(O)=O)C(O)=O UDFNOXIWFOPREQ-UHFFFAOYSA-N 0.000 description 1
- USYAMXSCYLGBPT-UHFFFAOYSA-L 3-carboxy-3-hydroxypentanedioate;tin(2+) Chemical compound [Sn+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O USYAMXSCYLGBPT-UHFFFAOYSA-L 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004343 Calcium peroxide Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 229910021594 Copper(II) fluoride Inorganic materials 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 235000002845 Dianthus plumarius Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 206010041857 Squamous cell carcinoma of the oral cavity Diseases 0.000 description 1
- 208000035518 Squamous cell carcinoma of the oropharynx Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108010036928 Thiorphan Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- WOHVONCNVLIHKY-UHFFFAOYSA-L [Ba+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Ba+2].[O-]Cl=O.[O-]Cl=O WOHVONCNVLIHKY-UHFFFAOYSA-L 0.000 description 1
- DIFOVZOIEPWVMA-UHFFFAOYSA-M [O-2].[Na+].[Zn+2].CCCCCCCCCCCCOS([O-])(=O)=O Chemical compound [O-2].[Na+].[Zn+2].CCCCCCCCCCCCOS([O-])(=O)=O DIFOVZOIEPWVMA-UHFFFAOYSA-M 0.000 description 1
- DTHZWUDUWBPDQI-UHFFFAOYSA-N [Zn].ClO Chemical compound [Zn].ClO DTHZWUDUWBPDQI-UHFFFAOYSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- 150000004974 alkaline earth metal peroxides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XUEHVOLRMXNRKQ-KHMAMNHCSA-N alpha cubebene Natural products CC(C)[C@@H]([C@H]12)CC[C@@H](C)[C@]32[C@@H]1C(C)=CC3 XUEHVOLRMXNRKQ-KHMAMNHCSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- NKCVNYJQLIWBHK-UHFFFAOYSA-N carbonodiperoxoic acid Chemical compound OOC(=O)OO NKCVNYJQLIWBHK-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- UOUJSJZBMCDAEU-UHFFFAOYSA-N chromium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+3].[Cr+3] UOUJSJZBMCDAEU-UHFFFAOYSA-N 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- GWFAVIIMQDUCRA-UHFFFAOYSA-L copper(ii) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 description 1
- AEJIMXVJZFYIHN-UHFFFAOYSA-N copper;dihydrate Chemical compound O.O.[Cu] AEJIMXVJZFYIHN-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- QSFOWAYMMZCQNF-UHFFFAOYSA-N delmopinol Chemical compound CCCC(CCC)CCCC1COCCN1CCO QSFOWAYMMZCQNF-UHFFFAOYSA-N 0.000 description 1
- 229960003854 delmopinol Drugs 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- PNOXNTGLSKTMQO-UHFFFAOYSA-L diacetyloxytin Chemical compound CC(=O)O[Sn]OC(C)=O PNOXNTGLSKTMQO-UHFFFAOYSA-L 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 description 1
- 229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical group [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940065115 grapefruit extract Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 description 1
- 229960004995 magnesium peroxide Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 description 1
- YRZGPQDNADQQOW-UHFFFAOYSA-L magnesium;potassium;phthalate Chemical compound [Mg+2].[K+].[O-]C(=O)C1=CC=CC=C1C([O-])=O YRZGPQDNADQQOW-UHFFFAOYSA-L 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229950002404 octapinol Drugs 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- UUZZMWZGAZGXSF-UHFFFAOYSA-N peroxynitric acid Chemical compound OON(=O)=O UUZZMWZGAZGXSF-UHFFFAOYSA-N 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
- 229960000897 phenazocine Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- COALSIYJQHMCDX-UHFFFAOYSA-L propanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)CC([O-])=O COALSIYJQHMCDX-UHFFFAOYSA-L 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 description 1
- 229950000975 salicylanilide Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- 229940050865 sodium phosphate,monobasic,monohydrate Drugs 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NYKCGQQJNVPOLU-ONTIZHBOSA-N spiradoline Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 NYKCGQQJNVPOLU-ONTIZHBOSA-N 0.000 description 1
- 229950006495 spiradoline Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 229940108184 stannous iodide Drugs 0.000 description 1
- RCIVOBGSMSSVTR-UHFFFAOYSA-L stannous sulfate Chemical compound [SnH2+2].[O-]S([O-])(=O)=O RCIVOBGSMSSVTR-UHFFFAOYSA-L 0.000 description 1
- 229940007163 stannous tartrate Drugs 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- UHCGLDSRFKGERO-UHFFFAOYSA-N strontium peroxide Chemical compound [Sr+2].[O-][O-] UHCGLDSRFKGERO-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical class OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 229930003945 thebaine Natural products 0.000 description 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
- 150000003584 thiosemicarbazones Chemical class 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229910000375 tin(II) sulfate Inorganic materials 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- MLIKYFGFHUYZAL-UHFFFAOYSA-K trisodium;hydron;phosphonato phosphate Chemical compound [Na+].[Na+].[Na+].OP([O-])(=O)OP([O-])([O-])=O MLIKYFGFHUYZAL-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- VSJRDSLPNMGNFG-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VSJRDSLPNMGNFG-UHFFFAOYSA-H 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229940030300 trolamine salicylate Drugs 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 229940085658 zinc citrate trihydrate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 229940105296 zinc peroxide Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
A dentifrice composition comprising, (a) a hydrophilic clay material, (b) a phytic acid compound, (c) an effective amount of an oral care active, and (d) a polar solvent carrier; wherein the composition is substantially free of abrasive material.
Description
DENTIFRICE COMPOSITION FREE OF ABRASIVE MATERIAL
FIELD OF THE INVENTION
The present invention relates to a dentifrice composition which is substantially free of abrasive material, and which can still maintain the cleaning benefits of a regular toothpaste.
BACKGROUND
Dentifrice compositions such as toothpastes are routinely used by consumers as part of their oral care hygiene regimens. It is well known that oral care products can provide both therapeutic and cosmetic hygiene benefits to consumers. Therapeutic benefits include, but are not limited to, caries prevention, gingivitis prevention, and hypersensitivity control. Cosmetic benefits include, but are not limited to, control of plaque and calculus formulation, removal and prevention of tooth stain, tooth whitening, breath freshening, and mouth feel aesthetics such as fresh sensation or slippery sensory feel.
Usage of abrasive material such as silica has long been considered critical for delivering the above mentioned therapeutic and cosmetic benefits of a dentifrice composition. Abrasive materials provide physical abrasion between toothbrush and teeth to clean plaque, stain, and calculus, while also build rheology and structure of the dentifrice for maintaining thermal stability of the overall formulation.
At the same time, however, usage of abrasive materials may also have certain negative effects to overall formulation. For example, the cost of silica itself is expensive. Further, silica adsorbs components in a typical dentifrice composition such as active agents, flavors, and foaming agents, thereby the concentrations of these components must be adjusted according to the foreseen loss by silica. Still further, certain active agents such as cetylpyridinium chloride have poor compatibility with silica, and therefore cannot be included in a dentifrice composition, despite its known effectiveness. In another aspect, it is a conception of the general consumer that abrasive materials may erode the enamel, if the teeth are brushed too intensively.
Based on the foregoing, there is a need for a dentifrice composition free of abrasives, which can still deliver the benefits of a regular dentifrice composition.
Specifically, there is a need for an abrasive-free dentifrice composition which is thermally stable, and which can deliver the same cleaning benefits as abrasive-including compositions on the market.
SUMMARY
The present invention is directed to a dentifrice composition comprising:
(a) a hydrophilic clay material;
(b) a phytic acid compound;
(c) an effective amount of an oral care active; and (d) a polar solvent carrier;
wherein the composition is substantially free of abrasive material.
The present invention is further directed to a method of cleaning the teeth absent an abrasive.
These and other features, aspects, and advantages of the present invention will become evident to those skilled in the art from a reading of the present disclosure with the appended claims.
DETAILED DESCRIPTION
The following is a list of definitions for terms used herein.
"Comprising" means that other steps and other ingredients which do not affect the end result can be added. This term encompasses the terms "consisting of" and "consisting essentially of".
All percentages are by weight of total composition unless specifically stated otherwise.
All cited references are incorporated herein by reference in their entireties.
Citation of any reference is not an admission regarding any determination as to its availability as prior art to the claimed invention.
All ratios are weight ratios unless specifically stated otherwise.
The present invention, in its product and process aspects, is described in detail as follows.
a) Hydrophilic Clay Material The composition of the present invention comprises a hydrophilic clay material which swells or thickens with the presence of a polar solvent, and acts as a binder for the dentifrice composition. The hydrophilic clay material may be any known that is safe and aesthetically acceptable for oral care use. The hydrophilic clay material provides a suitable rheology for the present dentifrice composition of various product form, including brushing liquids, gels, and toothpaste, having a viscosity of from about 1 mPas to about 450,000 Pas as measured by Brookfield viscometer with T-E spindle. In one highly preferred embodiment, the present dentifrice composition is a gel or toothpaste of suitable body and viscosity, the viscosity being from about 10,000 Pas to about 450,000 Pas, preferably from about 10,000 Pas to about 250,000 Pas. Additional binders may be added to provide such suitable rheology, as later discussed.
It has been surprisingly found that, hydrophilic clay material provides the above mentioned suitable stability at relatively low level, and relatively low cost, without the existence of an abrasive material in the composition.
The hydrophilic clay material is preferably comprised, by weight of the entire composition, at from about 0.01% to about 10%, preferably from about 1% to about 5%.
Hydrophilic clay materials useful herein include natural and synthesized layered silicate minerals, fumed silicas, thickening precipitated silica, and mixtures thereof.
Layered silicate minerals may be naturally occurred, or synthesized to have magnesium substituted with certain portions of the mineral. The fumed silicas are those that provide very little to no abrasive function having a particle size of smaller than about 5 m, typically from about 1 nm to about 1 m. The thickening precipitated silica are those having a DOA value of at least about 150 mf/100g, preferably at least about 250 mf/100g, and having a particle size of about 1 m to about 50 m. The thickening precipitated silica can be distinguished from abrasive silica material, due to its high oil absorbing capability, as defined by the DOA
value. Such capability provides thickening property.
Commercially available hydrophilic clay materials useful herein include synthesized layered magnesium silicate by the tradename LAPONITE series available from Rockwood Additives Limited and Southern Clay Company, fumed silica having an average particle size of about 12 nm by the tradename AEROSOL series and CAB-O-SIL available from Cabot &
Degussa Corporation, amorphous precipitated silica by the tradename ZEODENT
165 from J.
M. Huber Company and SYLOX 15 from Grace Davision, and precipitated silica by the tradename TIXOSIL from Rhodia.
b) Phytic Acid Compound The composition of the present invention comprises a phytic acid compound in an amount it provides effective cleaning to the teeth. Phytic acid, also known as myo-inositol hexaphosphate, or inositol hexaphosphoric acid, is a natural vegetable based biodegradable chelating agent in liquid form with chelating performance comparable to that of EDTA. Origin of vegetables from which phytic acid compounds can be found, include cereal grains, legumes, nuts oilseeds, pollen, spore, and organic soils.
The phytic acid compound herein can be phytic acid itself and/or its orally acceptable salts including, but not limited to, alkali metal salts and alkali earth metal salts. Useful phytic acid salts include sodium phytate, potassium phytate, magnesium phytate, calcium phytate, stannous phytate, zinc phytate, copper phytate, ferrum phytate, and mixtures thereof.
It has been surprisingly found that the phytic acid compound provides good cleaning effect in the present abrasive free composition without consumer noticeable staining, and is compatible with the present polar solvent carrier, as well as a wide variety of oral care active ingredients. Without being bound by theory, it is believed that the phytic acid compound provides unique good cleaning due to its liquid form, by flowing between teeth. Such flowing is believed to provide cleaning in a way differently from solid abrasive materials. Further, it is believed that the phytic acid compound provides a positive effect for protecting tooth enamel from acid dissolution, and anti-tartar effect.
Commercially available phytic acid compounds useful herein include phytic acid solution, sodium phytate, magnesium phytate, calcium phytate, and stannous phytate available from Sichuan Chengdu Yason, Shikishima Starch Manufacturing Company, and Nibbio.
c) Oral Care Active The composition of the present invention comprises an oral care active which delivers the intended therapeutic oral care benefit. Oral care actives useful herein include anti-calculus agents, stannous ion sources, fluoride ion sources, whitening agents, anti-microbial agents, anti-plaque agents, anti-inflammatory agents, nutrients, antioxidants, anti-viral agents, analgesic and anesthetic agents, zinc-containing layered material, and mixtures thereof.
c-1) Anticalculus Agent Useful oral care agents herein include an anti-calculus agent, which in one embodiment may be present from about 0.05% to about 50%, by weight of the oral care composition, in another embodiment is from about 0.05% to about 25%. The anti-calculus agent may be selected from the group consisting of polyphosphates (including pyrophosphates) and salts thereof; polyamino propane sulfonic acid (AMPS) and salts thereof; polyolefin sulfonates and salts thereof; polyvinyl phosphates and salts thereof; polyolefin phosphates and salts thereof;
diphosphonates and salts thereof; phosphonoalkane carboxylic acid and salts thereof;
polyphosphonates and salts thereof; polyvinyl phosphonates and salts thereof;
polyolefin phosphonates and salts thereof; polypeptides; and mixtures thereof. In one embodiment, the salts are alkali metal salts. Polyphosphates are generally employed as their wholly or partially neutralized water-soluble alkali metal salts such as potassium, sodium, ammonium salts, and mixtures thereof. The inorganic polyphosphate salts include alkali metal (e.g.
sodium) tripolyphosphate, tetrapolyphosphate, dialkyl metal (e.g. disodium) diacid, trialkyl metal (e.g.
trisodium) monoacid, potassium hydrogen phosphate, sodium hydrogen phosphate, and alkali metal (e.g. sodium) hexametaphosphate, and mixtures thereof. Polyphosphates larger than tetrapolyphosphate usually occur as amorphous glassy materials. In one embodiment the polyphosphates are those manufactured by FMC Corporation, which are commercially known as Sodaphos (n=6), Hexaphos (n=13), and Glass H(n=21, sodium hexametaphosphate), and mixtures thereof. The pyrophosphate salts useful in the present invention include, alkali metal pyrophosphates, di-, tri-, and mono-potassium or sodium pyrophosphates, dialkali metal pyrophosphate salts, tetraalkali metal pyrophosphate salts, and mixtures thereof. In one embodiment the pyrophosphate salt is selected from the group consisting of trisodium pyrophosphate, disodium dihydrogen pyrophosphate (Na2H2P2O7), dipotassium pyrophosphate, tetrasodium pyrophosphate (Na4P2O7), tetrapotassium pyrophosphate (K4P207), and mixtures thereof. Polyolefin sulfonates include those wherein the olefin group contains 2 or more carbon atoms, and salts thereof. Polyolefin phosphonates include those wherein the olefin group contains 2 or more carbon atoms. Polyvinylphosphonates include polyvinylphosphonic acid.
Diphosphonates and salts thereof include azocycloalkane-2,2-diphosphonic acids and salts thereof, ions of azocycloalkane-2,2-diphosphonic acids and salts thereof, azacyclohexane-2,2-diphosphonic acid, azacyclopentane-2,2-diphosphonic acid, N-methyl-azacyclopentane-2,3-diphosphonic acid, EHDP (ethane- 1-hydroxy- 1, 1,-diphosphonic acid), AHP
(azacycloheptane-2,2-diphosphonic acid), ethane-1-amino-l,1-diphosphonate, dichloromethane-diphosphonate, etc. Phosphonoalkane carboxylic acid or their alkali metal salts include PPTA
(phosphonopropane tricarboxylic acid), PBTA (phosphonobutane-1,2,4-tricarboxylic acid), each as acid or alkali metal salts. Polyolefin phosphates include those wherein the olefin group contains 2 or more carbon atoms. Other useful material include synthetic anionic polymers, including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez), as described, for example, in U.S. Patent 4,627,977, as well as, e.g., polyamino propoane sulfonic acid (AMPS), zinc citrate trihydrate, polyphosphates (e.g., tripolyphosphate;
hexametaphosphate), diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof. Additionally, the oral care composition can include a polymer carrier, such as those described in U.S. Patent Nos. 6,682,722 and 6,589,512 and U.S.
Application Nos. 10/424,640 and 10/430,617.
c-2) Stannous Ion Source Useful oral care agents herein include a stannous ion source. The stannous ions may be provided from stannous fluoride and/or other stannous salts. Stannous fluoride has been found to help in the reduction of gingivitis, plaque, sensitivity, and in improved breath benefits. The stannous ions provided in an oral composition will provide efficacy to a subject using the composition. Although efficacy could include benefits other than the reduction in gingivitis, efficacy is defined as a noticeable amount of reduction in in situ plaque metabolism.
Formulations providing such efficacy typically include stannous levels provided by stannous fluoride and/or other stannous salts ranging from about 3,000 ppm to about 15,000 ppm stannous ions in the total composition. Below about 3,000 ppm stannous the efficacy of the stannous is not sufficient. The stannous ion is present in an amount of from about 4,000 ppm to about 12,000 ppm, in one embodiment from about 5,000 ppm to about 10,000 ppm. Other stannous salts include organic stannous carboxylates, such as stannous acetate, stannous gluconate, stannous oxalate, stannous malonate, stannous citrate, stannous ethylene glycoxide, stannous formate, stannous sulfate, stannous lactate, stannous tartrate, and the like.
Other stannous ion sources include, stannous halides such as stannous chlorides, stannous bromide, stannous iodide and stannous chloride dihydride. In one embodiment the stannous ion source is stannous fluoride in another embodiment, stannous chloride dihydrate. The combined stannous salts may be present in an amount of from about 0.001 Io to about 11%, by weight of the compositions. The stannous salts may, in one embodiment, be present in an amount of from about 0.01 Io to about 7 Io, in another embodiment from about 0.1 Io to about 5 Io, and in another embodiment from about 1.5% to about 3%, by weight of the composition.
c-3) Fluoride Ion Source Useful oral care agents herein include a fluoride ion source to provide an anticaries effect.
Among these materials are inorganic fluoride salts, such as soluble alkali metal fluoride salts, for example, sodium fluoride, potassium fluoride, sodium monofluorophosphate and sodium hexafluorosilicate. Alkali metal fluorides, such as sodium fluoride, sodium monofluorophosphate, sodium hexafluorosilicate and mixtures thereof, are preferred.
The amount of fluorine-providing salt is generally present in the oral composition at a concentration of about 0.0 to about 3.0% by weight. Any suitable minimum amount of such salt may be used, but it is preferable to employ sufficient fluoride salt to release from about 50ppm to about 3500 ppm, preferably from about 300ppm to 2,000ppm, of fluoride ion.
c-4) Whitenin Ment Useful oral care agents herein include a whitening agent The actives suitable for whitening are selected from the group consisting of alkali metal and alkaline earth metal peroxides, metal chlorites, perborates inclusive of mono and tetrahydrates, perphoshates, percarbonates, peroxyacids, alkali metal and persulfates, such as ammonium, potassium, sodium and lithium persulfates, and combinations thereof. Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, carbamide peroxide, magnesium peroxide, zinc peroxide, strontium peroxide and mixtures thereof. In one embodiment the peroxide compound is carbamide peroxide. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite.
Additional whitening actives may be hypochlorite and chlorine dioxide. In one embodiment the chlorite is sodium chlorite. In another embodiment the percarbonate is sodium percarbonate. In one embodiment the persulfates are oxones. The level of these substances is dependent on the available oxygen or chlorine, respectively, that the molecule is capable of providing to bleach the stain. In one embodiment the whitening agents may be present at levels from about 0.01% to about 40%, in another embodiment from about 0.1% to about 20%, in another embodiment form about 0.5% to about 10%, and in another embodiment from about 4% to about 7%, by weight of the composition.
c-5) Anti-Microbial Ment Useful oral care agents herein include other anti-microbial agents. Such agents may include, but are not limited to: 5-chloro-2-(2,4-dichlorophenoxy)-phenol, commonly referred to as triclosan; 8-hydroxyquinoline and its salts; copper II compounds, including, but not limited to, copper(II) chloride, copper(II) sulfate, copper(II) acetate, copper(II) fluoride and copper(II) hydroxide; phthalic acid and its salts including, but not limited to those disclosed in U.S. Pat.
4,994,262, including magnesium monopotassium phthalate; chlorhexidine;
alexidine;
hexetidine; sanguinarine; benzalkonium chloride; salicylanilide; domiphen bromide;
FIELD OF THE INVENTION
The present invention relates to a dentifrice composition which is substantially free of abrasive material, and which can still maintain the cleaning benefits of a regular toothpaste.
BACKGROUND
Dentifrice compositions such as toothpastes are routinely used by consumers as part of their oral care hygiene regimens. It is well known that oral care products can provide both therapeutic and cosmetic hygiene benefits to consumers. Therapeutic benefits include, but are not limited to, caries prevention, gingivitis prevention, and hypersensitivity control. Cosmetic benefits include, but are not limited to, control of plaque and calculus formulation, removal and prevention of tooth stain, tooth whitening, breath freshening, and mouth feel aesthetics such as fresh sensation or slippery sensory feel.
Usage of abrasive material such as silica has long been considered critical for delivering the above mentioned therapeutic and cosmetic benefits of a dentifrice composition. Abrasive materials provide physical abrasion between toothbrush and teeth to clean plaque, stain, and calculus, while also build rheology and structure of the dentifrice for maintaining thermal stability of the overall formulation.
At the same time, however, usage of abrasive materials may also have certain negative effects to overall formulation. For example, the cost of silica itself is expensive. Further, silica adsorbs components in a typical dentifrice composition such as active agents, flavors, and foaming agents, thereby the concentrations of these components must be adjusted according to the foreseen loss by silica. Still further, certain active agents such as cetylpyridinium chloride have poor compatibility with silica, and therefore cannot be included in a dentifrice composition, despite its known effectiveness. In another aspect, it is a conception of the general consumer that abrasive materials may erode the enamel, if the teeth are brushed too intensively.
Based on the foregoing, there is a need for a dentifrice composition free of abrasives, which can still deliver the benefits of a regular dentifrice composition.
Specifically, there is a need for an abrasive-free dentifrice composition which is thermally stable, and which can deliver the same cleaning benefits as abrasive-including compositions on the market.
SUMMARY
The present invention is directed to a dentifrice composition comprising:
(a) a hydrophilic clay material;
(b) a phytic acid compound;
(c) an effective amount of an oral care active; and (d) a polar solvent carrier;
wherein the composition is substantially free of abrasive material.
The present invention is further directed to a method of cleaning the teeth absent an abrasive.
These and other features, aspects, and advantages of the present invention will become evident to those skilled in the art from a reading of the present disclosure with the appended claims.
DETAILED DESCRIPTION
The following is a list of definitions for terms used herein.
"Comprising" means that other steps and other ingredients which do not affect the end result can be added. This term encompasses the terms "consisting of" and "consisting essentially of".
All percentages are by weight of total composition unless specifically stated otherwise.
All cited references are incorporated herein by reference in their entireties.
Citation of any reference is not an admission regarding any determination as to its availability as prior art to the claimed invention.
All ratios are weight ratios unless specifically stated otherwise.
The present invention, in its product and process aspects, is described in detail as follows.
a) Hydrophilic Clay Material The composition of the present invention comprises a hydrophilic clay material which swells or thickens with the presence of a polar solvent, and acts as a binder for the dentifrice composition. The hydrophilic clay material may be any known that is safe and aesthetically acceptable for oral care use. The hydrophilic clay material provides a suitable rheology for the present dentifrice composition of various product form, including brushing liquids, gels, and toothpaste, having a viscosity of from about 1 mPas to about 450,000 Pas as measured by Brookfield viscometer with T-E spindle. In one highly preferred embodiment, the present dentifrice composition is a gel or toothpaste of suitable body and viscosity, the viscosity being from about 10,000 Pas to about 450,000 Pas, preferably from about 10,000 Pas to about 250,000 Pas. Additional binders may be added to provide such suitable rheology, as later discussed.
It has been surprisingly found that, hydrophilic clay material provides the above mentioned suitable stability at relatively low level, and relatively low cost, without the existence of an abrasive material in the composition.
The hydrophilic clay material is preferably comprised, by weight of the entire composition, at from about 0.01% to about 10%, preferably from about 1% to about 5%.
Hydrophilic clay materials useful herein include natural and synthesized layered silicate minerals, fumed silicas, thickening precipitated silica, and mixtures thereof.
Layered silicate minerals may be naturally occurred, or synthesized to have magnesium substituted with certain portions of the mineral. The fumed silicas are those that provide very little to no abrasive function having a particle size of smaller than about 5 m, typically from about 1 nm to about 1 m. The thickening precipitated silica are those having a DOA value of at least about 150 mf/100g, preferably at least about 250 mf/100g, and having a particle size of about 1 m to about 50 m. The thickening precipitated silica can be distinguished from abrasive silica material, due to its high oil absorbing capability, as defined by the DOA
value. Such capability provides thickening property.
Commercially available hydrophilic clay materials useful herein include synthesized layered magnesium silicate by the tradename LAPONITE series available from Rockwood Additives Limited and Southern Clay Company, fumed silica having an average particle size of about 12 nm by the tradename AEROSOL series and CAB-O-SIL available from Cabot &
Degussa Corporation, amorphous precipitated silica by the tradename ZEODENT
165 from J.
M. Huber Company and SYLOX 15 from Grace Davision, and precipitated silica by the tradename TIXOSIL from Rhodia.
b) Phytic Acid Compound The composition of the present invention comprises a phytic acid compound in an amount it provides effective cleaning to the teeth. Phytic acid, also known as myo-inositol hexaphosphate, or inositol hexaphosphoric acid, is a natural vegetable based biodegradable chelating agent in liquid form with chelating performance comparable to that of EDTA. Origin of vegetables from which phytic acid compounds can be found, include cereal grains, legumes, nuts oilseeds, pollen, spore, and organic soils.
The phytic acid compound herein can be phytic acid itself and/or its orally acceptable salts including, but not limited to, alkali metal salts and alkali earth metal salts. Useful phytic acid salts include sodium phytate, potassium phytate, magnesium phytate, calcium phytate, stannous phytate, zinc phytate, copper phytate, ferrum phytate, and mixtures thereof.
It has been surprisingly found that the phytic acid compound provides good cleaning effect in the present abrasive free composition without consumer noticeable staining, and is compatible with the present polar solvent carrier, as well as a wide variety of oral care active ingredients. Without being bound by theory, it is believed that the phytic acid compound provides unique good cleaning due to its liquid form, by flowing between teeth. Such flowing is believed to provide cleaning in a way differently from solid abrasive materials. Further, it is believed that the phytic acid compound provides a positive effect for protecting tooth enamel from acid dissolution, and anti-tartar effect.
Commercially available phytic acid compounds useful herein include phytic acid solution, sodium phytate, magnesium phytate, calcium phytate, and stannous phytate available from Sichuan Chengdu Yason, Shikishima Starch Manufacturing Company, and Nibbio.
c) Oral Care Active The composition of the present invention comprises an oral care active which delivers the intended therapeutic oral care benefit. Oral care actives useful herein include anti-calculus agents, stannous ion sources, fluoride ion sources, whitening agents, anti-microbial agents, anti-plaque agents, anti-inflammatory agents, nutrients, antioxidants, anti-viral agents, analgesic and anesthetic agents, zinc-containing layered material, and mixtures thereof.
c-1) Anticalculus Agent Useful oral care agents herein include an anti-calculus agent, which in one embodiment may be present from about 0.05% to about 50%, by weight of the oral care composition, in another embodiment is from about 0.05% to about 25%. The anti-calculus agent may be selected from the group consisting of polyphosphates (including pyrophosphates) and salts thereof; polyamino propane sulfonic acid (AMPS) and salts thereof; polyolefin sulfonates and salts thereof; polyvinyl phosphates and salts thereof; polyolefin phosphates and salts thereof;
diphosphonates and salts thereof; phosphonoalkane carboxylic acid and salts thereof;
polyphosphonates and salts thereof; polyvinyl phosphonates and salts thereof;
polyolefin phosphonates and salts thereof; polypeptides; and mixtures thereof. In one embodiment, the salts are alkali metal salts. Polyphosphates are generally employed as their wholly or partially neutralized water-soluble alkali metal salts such as potassium, sodium, ammonium salts, and mixtures thereof. The inorganic polyphosphate salts include alkali metal (e.g.
sodium) tripolyphosphate, tetrapolyphosphate, dialkyl metal (e.g. disodium) diacid, trialkyl metal (e.g.
trisodium) monoacid, potassium hydrogen phosphate, sodium hydrogen phosphate, and alkali metal (e.g. sodium) hexametaphosphate, and mixtures thereof. Polyphosphates larger than tetrapolyphosphate usually occur as amorphous glassy materials. In one embodiment the polyphosphates are those manufactured by FMC Corporation, which are commercially known as Sodaphos (n=6), Hexaphos (n=13), and Glass H(n=21, sodium hexametaphosphate), and mixtures thereof. The pyrophosphate salts useful in the present invention include, alkali metal pyrophosphates, di-, tri-, and mono-potassium or sodium pyrophosphates, dialkali metal pyrophosphate salts, tetraalkali metal pyrophosphate salts, and mixtures thereof. In one embodiment the pyrophosphate salt is selected from the group consisting of trisodium pyrophosphate, disodium dihydrogen pyrophosphate (Na2H2P2O7), dipotassium pyrophosphate, tetrasodium pyrophosphate (Na4P2O7), tetrapotassium pyrophosphate (K4P207), and mixtures thereof. Polyolefin sulfonates include those wherein the olefin group contains 2 or more carbon atoms, and salts thereof. Polyolefin phosphonates include those wherein the olefin group contains 2 or more carbon atoms. Polyvinylphosphonates include polyvinylphosphonic acid.
Diphosphonates and salts thereof include azocycloalkane-2,2-diphosphonic acids and salts thereof, ions of azocycloalkane-2,2-diphosphonic acids and salts thereof, azacyclohexane-2,2-diphosphonic acid, azacyclopentane-2,2-diphosphonic acid, N-methyl-azacyclopentane-2,3-diphosphonic acid, EHDP (ethane- 1-hydroxy- 1, 1,-diphosphonic acid), AHP
(azacycloheptane-2,2-diphosphonic acid), ethane-1-amino-l,1-diphosphonate, dichloromethane-diphosphonate, etc. Phosphonoalkane carboxylic acid or their alkali metal salts include PPTA
(phosphonopropane tricarboxylic acid), PBTA (phosphonobutane-1,2,4-tricarboxylic acid), each as acid or alkali metal salts. Polyolefin phosphates include those wherein the olefin group contains 2 or more carbon atoms. Other useful material include synthetic anionic polymers, including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez), as described, for example, in U.S. Patent 4,627,977, as well as, e.g., polyamino propoane sulfonic acid (AMPS), zinc citrate trihydrate, polyphosphates (e.g., tripolyphosphate;
hexametaphosphate), diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof. Additionally, the oral care composition can include a polymer carrier, such as those described in U.S. Patent Nos. 6,682,722 and 6,589,512 and U.S.
Application Nos. 10/424,640 and 10/430,617.
c-2) Stannous Ion Source Useful oral care agents herein include a stannous ion source. The stannous ions may be provided from stannous fluoride and/or other stannous salts. Stannous fluoride has been found to help in the reduction of gingivitis, plaque, sensitivity, and in improved breath benefits. The stannous ions provided in an oral composition will provide efficacy to a subject using the composition. Although efficacy could include benefits other than the reduction in gingivitis, efficacy is defined as a noticeable amount of reduction in in situ plaque metabolism.
Formulations providing such efficacy typically include stannous levels provided by stannous fluoride and/or other stannous salts ranging from about 3,000 ppm to about 15,000 ppm stannous ions in the total composition. Below about 3,000 ppm stannous the efficacy of the stannous is not sufficient. The stannous ion is present in an amount of from about 4,000 ppm to about 12,000 ppm, in one embodiment from about 5,000 ppm to about 10,000 ppm. Other stannous salts include organic stannous carboxylates, such as stannous acetate, stannous gluconate, stannous oxalate, stannous malonate, stannous citrate, stannous ethylene glycoxide, stannous formate, stannous sulfate, stannous lactate, stannous tartrate, and the like.
Other stannous ion sources include, stannous halides such as stannous chlorides, stannous bromide, stannous iodide and stannous chloride dihydride. In one embodiment the stannous ion source is stannous fluoride in another embodiment, stannous chloride dihydrate. The combined stannous salts may be present in an amount of from about 0.001 Io to about 11%, by weight of the compositions. The stannous salts may, in one embodiment, be present in an amount of from about 0.01 Io to about 7 Io, in another embodiment from about 0.1 Io to about 5 Io, and in another embodiment from about 1.5% to about 3%, by weight of the composition.
c-3) Fluoride Ion Source Useful oral care agents herein include a fluoride ion source to provide an anticaries effect.
Among these materials are inorganic fluoride salts, such as soluble alkali metal fluoride salts, for example, sodium fluoride, potassium fluoride, sodium monofluorophosphate and sodium hexafluorosilicate. Alkali metal fluorides, such as sodium fluoride, sodium monofluorophosphate, sodium hexafluorosilicate and mixtures thereof, are preferred.
The amount of fluorine-providing salt is generally present in the oral composition at a concentration of about 0.0 to about 3.0% by weight. Any suitable minimum amount of such salt may be used, but it is preferable to employ sufficient fluoride salt to release from about 50ppm to about 3500 ppm, preferably from about 300ppm to 2,000ppm, of fluoride ion.
c-4) Whitenin Ment Useful oral care agents herein include a whitening agent The actives suitable for whitening are selected from the group consisting of alkali metal and alkaline earth metal peroxides, metal chlorites, perborates inclusive of mono and tetrahydrates, perphoshates, percarbonates, peroxyacids, alkali metal and persulfates, such as ammonium, potassium, sodium and lithium persulfates, and combinations thereof. Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, carbamide peroxide, magnesium peroxide, zinc peroxide, strontium peroxide and mixtures thereof. In one embodiment the peroxide compound is carbamide peroxide. Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite.
Additional whitening actives may be hypochlorite and chlorine dioxide. In one embodiment the chlorite is sodium chlorite. In another embodiment the percarbonate is sodium percarbonate. In one embodiment the persulfates are oxones. The level of these substances is dependent on the available oxygen or chlorine, respectively, that the molecule is capable of providing to bleach the stain. In one embodiment the whitening agents may be present at levels from about 0.01% to about 40%, in another embodiment from about 0.1% to about 20%, in another embodiment form about 0.5% to about 10%, and in another embodiment from about 4% to about 7%, by weight of the composition.
c-5) Anti-Microbial Ment Useful oral care agents herein include other anti-microbial agents. Such agents may include, but are not limited to: 5-chloro-2-(2,4-dichlorophenoxy)-phenol, commonly referred to as triclosan; 8-hydroxyquinoline and its salts; copper II compounds, including, but not limited to, copper(II) chloride, copper(II) sulfate, copper(II) acetate, copper(II) fluoride and copper(II) hydroxide; phthalic acid and its salts including, but not limited to those disclosed in U.S. Pat.
4,994,262, including magnesium monopotassium phthalate; chlorhexidine;
alexidine;
hexetidine; sanguinarine; benzalkonium chloride; salicylanilide; domiphen bromide;
cetylpyridinium chloride (CPC); tetradecylpyridinium chloride (TPC); N-tetradecyl-4-ethylpyridinium chloride (TDEPC); octenidine; iodine; sulfonamides;
bisbiguanides; phenolics;
delmopinol, octapinol, and other piperidino derivatives; niacin preparations;
zinc or stannous ion agents such as zinc oxide, zinc lactate and zinc citrate; nystatin; grapefruit extract; apple extract;
thyme oil; thymol; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kanamycin, cetylpyridinium chloride, and clindamycin; analogs and salts of the above; essential oils including thymol, geraniol, carvacrol, citral, hinokitiol, eucalyptol, catechol (particularly 4-allyl catechol) and mixtures thereof; methyl salicylate; hydrogen peroxide; metal salts of chlorite; and mixtures of all of the above. Anti-microbial components may be present from about 0.001% to about 20% by weight of the composition.
c-6) Anti-Plaque Agent Useful oral care agents herein include other anti-plaque agent such as dimethyl isosorbide, copper salts, strontium salts, magnesium salts or a dimethicone copolyol. The dimethicone copolyol is selected from C12 to C20 alkyl dimethicone copolyols and mixtures thereof. In one embodiment the dimethicone copolyol is cetyl dimethicone copolyol marketed under the Trade Name Abil EM90. The dimethicone copolyol in one embodiment can be present in a level of from about 0.001 Io to about 25 Io, in another embodiment from about 0.01 Io to about 5%, and in another embodiment from about 0.1% to about 1.5% by weight of the composition.
c-7) Anti-Inflammatory Agent Useful oral care agents herein include anti-inflammatory agents. Such agents may include, but are not limited to, non-steroidal anti-inflammatory agents oxicams, salicylates, propionic acids, acetic acids and fenamates. Such NSAIDs include but are not limited to ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, ketoprofen, fenoprofen, piroxicam, nabumetone, aspirin, diflunisal, meclofenamate, mefenamic acid, oxyphenbutazone, phenylbutazone and acetaminophen. Use of NSAIDs such as ketorolac are claimed in U.S. Patent 5,626,838. Disclosed therein are methods of preventing and/or treating primary and reoccurring squamous cell carcinoma of the oral cavity or oropharynx by topical administration to the oral cavity or oropharynx of an effective amount of an NSAID. Suitable steroidal anti-inflammatory agents include corticosteroids, such as fluccinolone, and hydrocortisone.
bisbiguanides; phenolics;
delmopinol, octapinol, and other piperidino derivatives; niacin preparations;
zinc or stannous ion agents such as zinc oxide, zinc lactate and zinc citrate; nystatin; grapefruit extract; apple extract;
thyme oil; thymol; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kanamycin, cetylpyridinium chloride, and clindamycin; analogs and salts of the above; essential oils including thymol, geraniol, carvacrol, citral, hinokitiol, eucalyptol, catechol (particularly 4-allyl catechol) and mixtures thereof; methyl salicylate; hydrogen peroxide; metal salts of chlorite; and mixtures of all of the above. Anti-microbial components may be present from about 0.001% to about 20% by weight of the composition.
c-6) Anti-Plaque Agent Useful oral care agents herein include other anti-plaque agent such as dimethyl isosorbide, copper salts, strontium salts, magnesium salts or a dimethicone copolyol. The dimethicone copolyol is selected from C12 to C20 alkyl dimethicone copolyols and mixtures thereof. In one embodiment the dimethicone copolyol is cetyl dimethicone copolyol marketed under the Trade Name Abil EM90. The dimethicone copolyol in one embodiment can be present in a level of from about 0.001 Io to about 25 Io, in another embodiment from about 0.01 Io to about 5%, and in another embodiment from about 0.1% to about 1.5% by weight of the composition.
c-7) Anti-Inflammatory Agent Useful oral care agents herein include anti-inflammatory agents. Such agents may include, but are not limited to, non-steroidal anti-inflammatory agents oxicams, salicylates, propionic acids, acetic acids and fenamates. Such NSAIDs include but are not limited to ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, ketoprofen, fenoprofen, piroxicam, nabumetone, aspirin, diflunisal, meclofenamate, mefenamic acid, oxyphenbutazone, phenylbutazone and acetaminophen. Use of NSAIDs such as ketorolac are claimed in U.S. Patent 5,626,838. Disclosed therein are methods of preventing and/or treating primary and reoccurring squamous cell carcinoma of the oral cavity or oropharynx by topical administration to the oral cavity or oropharynx of an effective amount of an NSAID. Suitable steroidal anti-inflammatory agents include corticosteroids, such as fluccinolone, and hydrocortisone.
c-8) Nutrients Useful oral care agents herein include nutrients which improve the condition of the oral cavity. Nutrients include minerals, vitamins, oral nutritional supplements, enteral nutritional supplements, and mixtures thereof. Useful minerals include calcium, phosphorus, zinc, manganese, potassium and mixtures thereof. Vitamins can be included with minerals or used independently. Suitable vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, and mixtures thereof. Oral nutritional supplements include amino acids, lipotropics, fish oil, and mixtures thereof. Amino acids include, but are not limited to L-Tryptophan, L-Lysine, Methionine, Threonine, Levocarnitine or L- carnitine and mixtures thereof. Lipotropics include, but are not limited to, choline, inositol, betaine, linoleic acid, linolenic acid, and mixtures thereof. Fish oil contains large amounts of Omega-3 (N-3) polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid.
Enteral nutritional supplements include, but are not limited to, protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides. Minerals, vitamins, oral nutritional supplements and enteral nutritional supplements are described in more detail in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (01997, pps. 3-17 and 54-57.
c-9) Antioxidants Useful oral care agents herein include antioxidants. Antioxidants are disclosed in texts such as Cadenas and Packer, The Handbook of Antioxidants, 1996 by Marcel Dekker, Inc.
Antioxidants useful in the present invention include, but are not limited to, Vitamin E, ascorbic acid, Uric acid, carotenoids, Vitamin A, flavonoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures thereof.
c-10) Anti-Viral Agents Useful oral care agents herein include an antiviral actives used to treat viral infections.
Such antiviral actives include, but are not limited to: phosphonoformic acid;
cyosine derivatives;
purine analogues, such as adenosine, guanosine and inosine analogues;
pyrimidine bases, such as citidine and thymidine; amantadines; rimantadine HC1; ribavirin; zanamivir;
oseltamivir phosphate; trifluridine; heterocyclic dyes; acyclovir; famciclovir;
valacyclovir, cidofovir;
ganciclovir; levimisole; idoxuridine; lipophilic (3-ketones; and thiosemicarbazones. These antiviral actives are described in Drug Facts and Comparisons (loose-leaf drug information service), Wolters Kluwer Company, St. Louis, Mo., 2001, pp. 1400-1423(b), and in Kirk-Othmer, Encyclopedia of Chemical Technology, Fourth Edition, Volume 3, Wiley-Interscience Publishers (1992), pp. 576-607.
c-11) AnaNesic and Anesthetic Ments Useful oral care agents herein include anti-pain or desensitizing agents.
Analgesics are agents that relieve pain by acting centrally to elevate pain threshold without disturbing consciousness or altering other sensory modalities. Such agents may include, but are not limited to: strontium chloride; potassium nitrate; sodium fluoride; sodium nitrate; acetanilide;
phenacetin; acertophan; thiorphan; spiradoline; aspirin; codeine; thebaine;
levorphenol;
hydromorphone; oxymorphone; phenazocine; fentanyl; buprenorphine; butaphanol;
nalbuphine;
pentazocine; natural herbs, such as gall nut; Asarum; Cubebin; Galanga;
scutellaria;
Liangniianzhen; and Baizhi. Anesthetic agents, or topical analgesics, such as acetaminophen, sodium salicylate, trolamine salicylate, lidocaine and benzocaine may also be present. These analgesic actives are described in detail in Kirk-Othmer, Encyclopedia of Chemical Technology, Fourth Edition, Volume 2, Wiley-Interscience Publishers (1992), pp. 729-737.
c-12) Zinc-containing Layered Material Useful as the oral care active herein are zinc-containing layered material which have effective anti-microbial and anti-gingivitis benefit due to high zinc lability. Those zinc-containing layered materials particularly useful herein are those having a relative zinc lability of greater than about 25%, have an average particle size of less than about 20 microns, and have a high surface area. In one preferred embodiment, the zinc-containing layered material herein is incorporated in compositions containing an anionic surfactant, as later discussed.
Zinc lability is a measure of the chemical availability of zinc ion. Soluble zinc salts that do not complex with other species in solution have a relative zinc lability, by definition, of 100%. The use of partially soluble forms of zinc salts and/or incorporation in a matrix with potential complexants generally lowers the zinc lability substantially below the defined 100%
maximum. Labile zinc is maintained by choice of an effective zinc-containing layered material or formation of an effective zinc-containing layered material in-situ by known methods.
Zinc lability is assessed by combining a diluted zinc-containing solution or dispersion with the metallochromic dye xylenol orange (XO) and measurement of the degree of color change under specified conditions. The magnitude of color formation is proportional to the level of labile zinc. The procedure developed has been optimized for aqueous surfactant formulations but may be adapted to other physical product forms as well.
A spectrophotometer is used to quantify the color change at 572 nm, the wavelength of optimum color change for XO. The spectrophotometer is set to zero absorbance at 572nm utilizing a product control as close in composition to the test product except excluding the potentially labile form of zinc. The control and test products are then treated identically as follows. A 50 1 product sample is dispensed into a jar and 95 nil of deaerated, distilled water are added and stirred. 5mL of a 23mg/mL xylenol orange stock solution at pH
5.0 is pipetted into the sample jar; this is considered time 0. The pH is then adjusted to 5.
50 0.01 using dilute HC1 or NaOH. After 10.0 minutes, a portion of the sample is filtered (0.45 ) and the absorbance measured at 572nm. The measured absorbance is then compared to a separately measured control to determine the relative zinc lability (zero TO 100%). The 100% lability control is prepared in a matrix similar to the test products but utilizing a soluble zinc material (such as zinc sulfate) incorporated at an equivalent level on a zinc basis.
The absorbance of the 100% lability control is measured as above for the test materials. The relative zinc lability is preferably greater than about 15%, more preferably greater than about 20%, and even more preferably greater than about 25%.
Using this methodology, the below examples demonstrate a material (basic zinc carbonate) that has intrinsically high lability in an anionic surfactant system compared to one (ZnO) with low intrinsic lability.
Relative Zinc Lability (%) Lability Benefit In Water In 6% sodium lauryl sulfate Zinc Oxide 86.3 1.5 NO
Basic zinc carbonate 100 37 YES
Zinc-containing layered structures are those with crystal growth primarily occurring in two dimensions. It is conventional to describe layer structures as not only those in which all the atoms are incorporated in well-defined layers, but also those in which there are ions or molecules between the layers, called gallery ions (A.F. Wells "Structural Inorganic Chemistry"
Clarendon Press, 1975). Zinc-containing layered materials (ZLM's) may have zinc incorporated in the layers and/or be components of the gallery ions.
Many ZLM's occur naturally as minerals. Common examples include hydrozincite (zinc carbonate hydroxide), basic zinc carbonate, aurichalcite (zinc copper carbonate hydroxide), rosasite (copper zinc carbonate hydroxide) and many related minerals that are zinc-containing.
Natural ZLM's can also occur wherein anionic layer species such as clay-type minerals (e.g., phyllosilicates) contain ion-exchanged zinc gallery ions. All of these natural materials can also be obtained synthetically or formed in situ in a composition or during a production process.
Another common class of ZLM's, which are often, but not always, synthetic, is layered doubly hydroxides, which are generally represented by the formula [M2+1-xM3+x(OH)2]x+
Am-x/m=nH2O and some or all of the divalent ions (M2+) would be represented as zinc ions (Crepaldi, EL, Pava, PC, Tronto, J, Valim, JB J. Colloid Interfac. Sci. 2002, 248, 429-42).
Yet another class of ZLM's can be prepared called hydroxy double salts (Morioka, H., Tagaya, H., Karasu, M, Kadokawa, J, Chiba, K Inorg. Chem. 1999, 38, 4211-6).
Hydroxy double salts can be represented by the general formula [M2+1-xM2+1+x(OH)3(1-y)]+ An-(1=3y)/n=nH2O where the two metal ion may be different; if they are the same and represented by zinc, the formula simplifies to [Znl+x(OH)2]2x+ 2x A-=nH2O. This latter formula represents (where x=0.4) common materials such as zinc hydroxychloride and zinc hydroxynitrate. These are related to hydrozincite as well wherein a divalent anion replace the monovalent anion. These materials can also be formed in situ in a composition or in or during a production process.
These classes of ZLM's represent relatively common examples of the general category and are not intended to be limiting as to the broader scope of materials which fit this definition.
Commercially available sources of basic zinc carbonate include Zinc Carbonate Basic (Cater Chemicals: Bensenville, IL, USA), Zinc Carbonate (Shepherd Chemicals:
Norwood, OH, USA), Zinc Carbonate (CPS Union Corp.: New York, NY, USA), Zinc Carbonate (Elementis Pigments: Durham, UK), and Zinc Carbonate AC (Bruggemann Chemical: Newtown Square, PA, USA).
Basic zinc carbonate, which also may be referred to commercially as "Zinc Carbonate"
or "Zinc Carbonate Basic" or "Zinc Hydroxy Carbonate", is a synthetic version consisting of materials similar to naturally occurring hydrozincite. The idealized stoichiometry is represented by Zn5(OH)6(C03)2 but the actual stoichiometric ratios can vary slightly and other impurities may be incorporated in the crystal lattice.
d) Polar Solvent Carrier The composition of the present invention comprises a polar solvent carrier for delivering the essential components, and for providing suitable rheology with the hydrophilic clay material.
The polar solvent also serves as solvent for incorporating water-soluble oral care actives and other components.
The polar solvent is comprised by weight of the entire composition at from about 1% to about 95%, preferably from about 30% to about 70%.
Polar solvents useful herein include water, polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, hexylene glycol, propane diol, ethylene glycol, diethylene glycol, dipropylene glycol, diglycerin, sorbitol, and other sugars which are in liquid form at ambient temperature. Also useful herein are water soluble alkoxylated nonionic polymers such as polyethylene glycol.
In one preferred embodiment, the present composition can comprise a relatively high level of water for providing a cost effective product. In such preferred embodiment, water is comprised at from about 30% to about 95%, more preferably from about 50 % to about 70 % of the entire composition.
Commercially available polar solvents herein include: glycerin available from Asahi Denka; propylene glycol with tradename LEXOL PG-865/855 available from Inolex, 1,2-PROPYLENE GLYCOL USP available from BASF; 1,3-butylene glycol available from Daisel Kagaku Kogyo; dipropylene glycol with the same tradename available from BASF;
diglycerin with tradename DIGLYCEROL available from Solvay GmbH, polyethylene glycol with the tradename PEG 300 available from Doe Chemical Company, and sorbitol 70%
solution available from Khalista (Liuzhou) Chemical Industries, Ltd.
Free of Abrasive Material The composition of the present invention is substantially free of abrasive material.
Namely, the composition of the present invention has no abrasive material that is intentionally included. It has been surprisingly found that, the present composition can deliver the benefits of a regular dentifrice composition, including those which are typically attributed to the use of abrasive material, such as cleaning, stain removal, plaque removal, calculus removal, and others.
Absence of abrasive material also accommodates inclusion of certain active agents such as cetylpyridinium chloride, which otherwise have poor compatibility with abrasive materials such as silica, and therefore cannot be included in a dentifrice composition.
Further, due to the absence of abrasive material, various aesthetics for the dentifrice product may be pursued. For example, a composition of transparent appearance may be made.
Abrasive materials from which the present composition is substantially free of, are defined as materials having a DOA value of no more than about 150 mf/100g, preferably no more than about 100 mf/100g, and having a particle size of from about 5 m to about 50 m.
Abrasive materials herein can be distinguished herein from those materials useful as binders.
Abrasive materials from which the present composition is free of, include:
inorganic minerals such as silica gels and precipitates; aluminas; hydrated alumina, calcium carbonate, titanium dioxide, talc, calcium dioxide, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde.
Additional Binder Material The composition of the present invention may further comprise an additional binder material which further builds rheology to the composition, or provides certain mouth feel upon usage. When included, the additional binder material is selected from those compatible with the hydrophilic clay material, and are included such that the total amount of hydrophilic clay material and additional binder material is from about 0.1% to about 10% of the entire composition, and provides a viscosity of from about 10,000 Pas to about 450,000 Pas, preferably from about 10,000 Pas to about 250,000 Pas.
Modified cellulose polymers are useful binder materials herein for building continuous structure to the composition. Modified cellulose polymers useful herein include sodium carboxymethyl cellulose, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl cellulose, hydroxypropy methyl cellulose, and hydroxyethyl cellulose.
Particularly useful commercially available materials include sodium carboxymethyl cellulose by the tradename BLANOSE series, OPTICEL 100, and AQUALON series from Hercules;
hydroxyethylpropylcellulose by the tradename KLUCEL series from Hercules, hydroxypropy methyl cellulose by the tradename TF-E25 from YIXING CITY NO.8 CHEMICAL PLANT
and by the tradename BENECEL series from Hercules.
Carboxyvinyl anionic polymers are useful binder materials herein for building a three dimentional structure in combination with the hydrophilic clay materials disclosed hereinabove.
Carboxyvinyl anionic polymers useful herein include those by the tradename of CARBOPOL
series (or CARBOMER) such as CARBOPOL 956, 934, 940, 941, 1342, ETD 2020, ULTREZ
Enteral nutritional supplements include, but are not limited to, protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides. Minerals, vitamins, oral nutritional supplements and enteral nutritional supplements are described in more detail in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., (01997, pps. 3-17 and 54-57.
c-9) Antioxidants Useful oral care agents herein include antioxidants. Antioxidants are disclosed in texts such as Cadenas and Packer, The Handbook of Antioxidants, 1996 by Marcel Dekker, Inc.
Antioxidants useful in the present invention include, but are not limited to, Vitamin E, ascorbic acid, Uric acid, carotenoids, Vitamin A, flavonoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures thereof.
c-10) Anti-Viral Agents Useful oral care agents herein include an antiviral actives used to treat viral infections.
Such antiviral actives include, but are not limited to: phosphonoformic acid;
cyosine derivatives;
purine analogues, such as adenosine, guanosine and inosine analogues;
pyrimidine bases, such as citidine and thymidine; amantadines; rimantadine HC1; ribavirin; zanamivir;
oseltamivir phosphate; trifluridine; heterocyclic dyes; acyclovir; famciclovir;
valacyclovir, cidofovir;
ganciclovir; levimisole; idoxuridine; lipophilic (3-ketones; and thiosemicarbazones. These antiviral actives are described in Drug Facts and Comparisons (loose-leaf drug information service), Wolters Kluwer Company, St. Louis, Mo., 2001, pp. 1400-1423(b), and in Kirk-Othmer, Encyclopedia of Chemical Technology, Fourth Edition, Volume 3, Wiley-Interscience Publishers (1992), pp. 576-607.
c-11) AnaNesic and Anesthetic Ments Useful oral care agents herein include anti-pain or desensitizing agents.
Analgesics are agents that relieve pain by acting centrally to elevate pain threshold without disturbing consciousness or altering other sensory modalities. Such agents may include, but are not limited to: strontium chloride; potassium nitrate; sodium fluoride; sodium nitrate; acetanilide;
phenacetin; acertophan; thiorphan; spiradoline; aspirin; codeine; thebaine;
levorphenol;
hydromorphone; oxymorphone; phenazocine; fentanyl; buprenorphine; butaphanol;
nalbuphine;
pentazocine; natural herbs, such as gall nut; Asarum; Cubebin; Galanga;
scutellaria;
Liangniianzhen; and Baizhi. Anesthetic agents, or topical analgesics, such as acetaminophen, sodium salicylate, trolamine salicylate, lidocaine and benzocaine may also be present. These analgesic actives are described in detail in Kirk-Othmer, Encyclopedia of Chemical Technology, Fourth Edition, Volume 2, Wiley-Interscience Publishers (1992), pp. 729-737.
c-12) Zinc-containing Layered Material Useful as the oral care active herein are zinc-containing layered material which have effective anti-microbial and anti-gingivitis benefit due to high zinc lability. Those zinc-containing layered materials particularly useful herein are those having a relative zinc lability of greater than about 25%, have an average particle size of less than about 20 microns, and have a high surface area. In one preferred embodiment, the zinc-containing layered material herein is incorporated in compositions containing an anionic surfactant, as later discussed.
Zinc lability is a measure of the chemical availability of zinc ion. Soluble zinc salts that do not complex with other species in solution have a relative zinc lability, by definition, of 100%. The use of partially soluble forms of zinc salts and/or incorporation in a matrix with potential complexants generally lowers the zinc lability substantially below the defined 100%
maximum. Labile zinc is maintained by choice of an effective zinc-containing layered material or formation of an effective zinc-containing layered material in-situ by known methods.
Zinc lability is assessed by combining a diluted zinc-containing solution or dispersion with the metallochromic dye xylenol orange (XO) and measurement of the degree of color change under specified conditions. The magnitude of color formation is proportional to the level of labile zinc. The procedure developed has been optimized for aqueous surfactant formulations but may be adapted to other physical product forms as well.
A spectrophotometer is used to quantify the color change at 572 nm, the wavelength of optimum color change for XO. The spectrophotometer is set to zero absorbance at 572nm utilizing a product control as close in composition to the test product except excluding the potentially labile form of zinc. The control and test products are then treated identically as follows. A 50 1 product sample is dispensed into a jar and 95 nil of deaerated, distilled water are added and stirred. 5mL of a 23mg/mL xylenol orange stock solution at pH
5.0 is pipetted into the sample jar; this is considered time 0. The pH is then adjusted to 5.
50 0.01 using dilute HC1 or NaOH. After 10.0 minutes, a portion of the sample is filtered (0.45 ) and the absorbance measured at 572nm. The measured absorbance is then compared to a separately measured control to determine the relative zinc lability (zero TO 100%). The 100% lability control is prepared in a matrix similar to the test products but utilizing a soluble zinc material (such as zinc sulfate) incorporated at an equivalent level on a zinc basis.
The absorbance of the 100% lability control is measured as above for the test materials. The relative zinc lability is preferably greater than about 15%, more preferably greater than about 20%, and even more preferably greater than about 25%.
Using this methodology, the below examples demonstrate a material (basic zinc carbonate) that has intrinsically high lability in an anionic surfactant system compared to one (ZnO) with low intrinsic lability.
Relative Zinc Lability (%) Lability Benefit In Water In 6% sodium lauryl sulfate Zinc Oxide 86.3 1.5 NO
Basic zinc carbonate 100 37 YES
Zinc-containing layered structures are those with crystal growth primarily occurring in two dimensions. It is conventional to describe layer structures as not only those in which all the atoms are incorporated in well-defined layers, but also those in which there are ions or molecules between the layers, called gallery ions (A.F. Wells "Structural Inorganic Chemistry"
Clarendon Press, 1975). Zinc-containing layered materials (ZLM's) may have zinc incorporated in the layers and/or be components of the gallery ions.
Many ZLM's occur naturally as minerals. Common examples include hydrozincite (zinc carbonate hydroxide), basic zinc carbonate, aurichalcite (zinc copper carbonate hydroxide), rosasite (copper zinc carbonate hydroxide) and many related minerals that are zinc-containing.
Natural ZLM's can also occur wherein anionic layer species such as clay-type minerals (e.g., phyllosilicates) contain ion-exchanged zinc gallery ions. All of these natural materials can also be obtained synthetically or formed in situ in a composition or during a production process.
Another common class of ZLM's, which are often, but not always, synthetic, is layered doubly hydroxides, which are generally represented by the formula [M2+1-xM3+x(OH)2]x+
Am-x/m=nH2O and some or all of the divalent ions (M2+) would be represented as zinc ions (Crepaldi, EL, Pava, PC, Tronto, J, Valim, JB J. Colloid Interfac. Sci. 2002, 248, 429-42).
Yet another class of ZLM's can be prepared called hydroxy double salts (Morioka, H., Tagaya, H., Karasu, M, Kadokawa, J, Chiba, K Inorg. Chem. 1999, 38, 4211-6).
Hydroxy double salts can be represented by the general formula [M2+1-xM2+1+x(OH)3(1-y)]+ An-(1=3y)/n=nH2O where the two metal ion may be different; if they are the same and represented by zinc, the formula simplifies to [Znl+x(OH)2]2x+ 2x A-=nH2O. This latter formula represents (where x=0.4) common materials such as zinc hydroxychloride and zinc hydroxynitrate. These are related to hydrozincite as well wherein a divalent anion replace the monovalent anion. These materials can also be formed in situ in a composition or in or during a production process.
These classes of ZLM's represent relatively common examples of the general category and are not intended to be limiting as to the broader scope of materials which fit this definition.
Commercially available sources of basic zinc carbonate include Zinc Carbonate Basic (Cater Chemicals: Bensenville, IL, USA), Zinc Carbonate (Shepherd Chemicals:
Norwood, OH, USA), Zinc Carbonate (CPS Union Corp.: New York, NY, USA), Zinc Carbonate (Elementis Pigments: Durham, UK), and Zinc Carbonate AC (Bruggemann Chemical: Newtown Square, PA, USA).
Basic zinc carbonate, which also may be referred to commercially as "Zinc Carbonate"
or "Zinc Carbonate Basic" or "Zinc Hydroxy Carbonate", is a synthetic version consisting of materials similar to naturally occurring hydrozincite. The idealized stoichiometry is represented by Zn5(OH)6(C03)2 but the actual stoichiometric ratios can vary slightly and other impurities may be incorporated in the crystal lattice.
d) Polar Solvent Carrier The composition of the present invention comprises a polar solvent carrier for delivering the essential components, and for providing suitable rheology with the hydrophilic clay material.
The polar solvent also serves as solvent for incorporating water-soluble oral care actives and other components.
The polar solvent is comprised by weight of the entire composition at from about 1% to about 95%, preferably from about 30% to about 70%.
Polar solvents useful herein include water, polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, hexylene glycol, propane diol, ethylene glycol, diethylene glycol, dipropylene glycol, diglycerin, sorbitol, and other sugars which are in liquid form at ambient temperature. Also useful herein are water soluble alkoxylated nonionic polymers such as polyethylene glycol.
In one preferred embodiment, the present composition can comprise a relatively high level of water for providing a cost effective product. In such preferred embodiment, water is comprised at from about 30% to about 95%, more preferably from about 50 % to about 70 % of the entire composition.
Commercially available polar solvents herein include: glycerin available from Asahi Denka; propylene glycol with tradename LEXOL PG-865/855 available from Inolex, 1,2-PROPYLENE GLYCOL USP available from BASF; 1,3-butylene glycol available from Daisel Kagaku Kogyo; dipropylene glycol with the same tradename available from BASF;
diglycerin with tradename DIGLYCEROL available from Solvay GmbH, polyethylene glycol with the tradename PEG 300 available from Doe Chemical Company, and sorbitol 70%
solution available from Khalista (Liuzhou) Chemical Industries, Ltd.
Free of Abrasive Material The composition of the present invention is substantially free of abrasive material.
Namely, the composition of the present invention has no abrasive material that is intentionally included. It has been surprisingly found that, the present composition can deliver the benefits of a regular dentifrice composition, including those which are typically attributed to the use of abrasive material, such as cleaning, stain removal, plaque removal, calculus removal, and others.
Absence of abrasive material also accommodates inclusion of certain active agents such as cetylpyridinium chloride, which otherwise have poor compatibility with abrasive materials such as silica, and therefore cannot be included in a dentifrice composition.
Further, due to the absence of abrasive material, various aesthetics for the dentifrice product may be pursued. For example, a composition of transparent appearance may be made.
Abrasive materials from which the present composition is substantially free of, are defined as materials having a DOA value of no more than about 150 mf/100g, preferably no more than about 100 mf/100g, and having a particle size of from about 5 m to about 50 m.
Abrasive materials herein can be distinguished herein from those materials useful as binders.
Abrasive materials from which the present composition is free of, include:
inorganic minerals such as silica gels and precipitates; aluminas; hydrated alumina, calcium carbonate, titanium dioxide, talc, calcium dioxide, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde.
Additional Binder Material The composition of the present invention may further comprise an additional binder material which further builds rheology to the composition, or provides certain mouth feel upon usage. When included, the additional binder material is selected from those compatible with the hydrophilic clay material, and are included such that the total amount of hydrophilic clay material and additional binder material is from about 0.1% to about 10% of the entire composition, and provides a viscosity of from about 10,000 Pas to about 450,000 Pas, preferably from about 10,000 Pas to about 250,000 Pas.
Modified cellulose polymers are useful binder materials herein for building continuous structure to the composition. Modified cellulose polymers useful herein include sodium carboxymethyl cellulose, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl cellulose, hydroxypropy methyl cellulose, and hydroxyethyl cellulose.
Particularly useful commercially available materials include sodium carboxymethyl cellulose by the tradename BLANOSE series, OPTICEL 100, and AQUALON series from Hercules;
hydroxyethylpropylcellulose by the tradename KLUCEL series from Hercules, hydroxypropy methyl cellulose by the tradename TF-E25 from YIXING CITY NO.8 CHEMICAL PLANT
and by the tradename BENECEL series from Hercules.
Carboxyvinyl anionic polymers are useful binder materials herein for building a three dimentional structure in combination with the hydrophilic clay materials disclosed hereinabove.
Carboxyvinyl anionic polymers useful herein include those by the tradename of CARBOPOL
series (or CARBOMER) such as CARBOPOL 956, 934, 940, 941, 1342, ETD 2020, ULTREZ
10" from Noveon Inc., CARBOPOL 934, 940, 974 P from B. F. Goodrich and SYNTHALEN K
available from 3V Company.
Natural gum derived anionic polymers are useful binder materials herein for effectively adding viscosity. Natural gum derived anionic polymers useful herein in clude carrageenan, xanthan gum, gellan gum, and locust bean gum. Particularly useful commercially available materials include xanthan gum by the tradename KELDENT series available from CP Kelco, and by the tradename RHODICARE series from Rhodia; gellan gum by the tradename KELCOGEL series from CP Kelco; and locust bean gum by the tradename GELLOID LB
series from FMC BioPolymer.
Also useful as binder material herein are starch and carrageenan. Carrageenan is commercially available by tradename VISCARI series and GELCARIN series from FMC
BioPolymer, by the tradename MEYPRO-SOL series from Meyhall AG, and by the tradename GENUVISCO series, GENU series and GENUTINE series from CP Kelco.
Additional Components The composition of the present invention may include other additional components, which may be selected by the artisan according to the desired characteristics of the final product and which are suitable for rendering the composition more cosmetically or aesthetically acceptable or to provide them with additional usage benefits. Such additional components generally are used individually at levels of no more than about 5% by weight of the composition.
Surfactants may be incorporated in the components of the present invention as an ingredient to aid in the thorough dispersion of the dentifrice throughout the oral cavity when applied thereto, as well as, to improve cosmetic acceptability and the foaming properties. The surfactants which can be included in the present composition include anionic, nonionic or amphoteric compounds, anionic compounds being preferred.
Suitable examples of anionic surfactants are higher alkyl sulfates such as potassium or sodium lauryl sulfate which is preferred, higher fatty acid monoglyceride monosulfates, such as the salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, alkyl sulfonates such as sodium dodecyl benzene sulfonate, higher fatty sulfoacetates, higher fatty acid esters of 1,2 dihydroxypropane sulfonate.
Examples of water soluble nonionic surfactants are condensation products of ethylene oxide with various hydrogen-containing compounds that are reactive therewith and have long hydrophobic chains (e.g., aliphatic chains of about 12 of 20 carbon atoms), which condensation products contain hydrophilic polyoxyethylene moieties, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides and other fatty moieties, and with propylene oxide and polypropylene oxides, e.g., Pluronic materials such as Pluronic F127.
The surfactant can be present in the present composition at a concentration of from about 0.5 to about 10.0% by weight, preferably about 1 to about 2% by weight.
Other ingredients which may be incorporated in the dentifrice composition of the present invention include pigments, dyes, flavoring and sweetening materials. For example, a striped product is obtained in accordance with the present invention wherein colorants of contrasting colors are incorporated in each of the components used in the practice of the present invention, the colorants being pharmacologically and physiologically nontoxic when used in the suggested amounts. Colorants used in the present invention include both pigments and dyes.
Pigments useful in the present invention include non-toxic, water insoluble inorganic pigments such as titanium dioxide and chromium oxide greens, ultramarine blues and pinks and ferric oxides as well as water insoluble dye lakes prepared by extending calcium or aluminum salts of FD&C dyes on alumina such as FD&C Green #1 lake, FD&C Blue #21ake, FD&C R&D
#30 lake, FD&C #5 Yellow and FD&C # Yellow 15 lake, The concentration of the dye in the present composition is no more than about 3% by weight. The pigments herein are distinguished from the abrasive materials, which the present composition is substantially free from, as pigments herein have a particle size in the range of from 100 to about 1000 microns, preferably from about 250 to about 500 microns. When present, the pigments are included in the present composition at from about 0.5% to about 3% by weight.
Any suitable flavoring or sweetening material may also be incorporated in the components of the present invention. Examples of suitable flavoring constituents are flavoring oils, e.g., oils of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon. Lemon, and orange, and methyl salicylate. Suitable sweetening agents include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, and sodium saccharin. Suitably, flavor and sweetening agents may together comprise from 0.01% to 5% by weight or more of the preparations.
Enzyme inhibitor, botanical extracts, natural herb extracts, and others may be included.
EXAMPLES
The following examples further describe and demonstrate the preferred embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration, and are not to be construed as liniitations of the present invention since many variations thereof are possible without departing from its spirit and scope.
The following dentifrice compositions are formed by the following components using the method of preparation described herein.
Compositions for Examples 1-5:
Component Ex.1 Ex.1 Ex.3 Ex. 4 Ex.5 Sodium Fluoride *1 0.243 0.243 0.243 0.243 0.243 Sorbitol (70% sol.) *2 39.299 39.299 25 20 Glycerin * 3 5 20 Polyethylene Glycol *4 10 Sodium Lauryl Sulfate (28% sol.) 5 7.5 1 7.5 10 *5 Sodium Carboxymethyl Cellulose 1.0 1.0 1 2.0 *6 Carbopol * 7 0.6 0.6 1.0 1.0 Xanthan Gum * 8 0.35 0.35 0.5 0.35 Carrageenan *9 0.5 Synthesized Layered Magnesium 1.0 1.0 0.4 0.5 Silicate 0.2% Fluoride *10 Synthesized Layered Magnesium 0.2 Silicate *11 Amorphous Precipitated Silica 0.5 *12 Fumed Silica *13 0.5 Mica, Titanium Dioxide Coated 0.5 *14 Sodium Hydroxide Solution 0.54 0.54 0.54 0.54 (50%) *15 Tetrasodium Pyrophosphate *16 0.05 0.05 0.05 0.05 Sodium Phosphate, Monobasic, 0.4 Monohydrate * 17 Tribasic Sodium Phosphate, NF 0.9 (Dodecahydrate) * 18 Flavor 0.80 0.80 0.50 0.80 1.00 Sodium Phytate 20% Solution * 19 5.0 2.5 25.0 2.5 1.25 Sodium Saccharin *20 0.25 0.25 0.25 0.25 0.25 Dyes 0.0008 0.0008 0.0008 0.0008 0.0008 Deionized Water QS to 100%
Compositions for Examples 6-10 Component Ex. 6 Ex. 7 Ex.8 Ex. 9 Ex. 10 Sodium Fluoride *1 0.243 0.243 0.243 Stannous Fluoride *21 0.454 0.454 Sorbitol (70% sol.) *2 39.299 39.299 39.299 39.299 39.299 Sodium Lauryl Sulfate (28% sol.) *5 1 3 5 7.5 10 Sodium Carboxymethyl Cellulose *6 2.0 2.0 1.0 1.0 1.0 Carbopol *7 0.6 0.6 0.6 Xanthan Gum *8 0.35 0.35 0.35 0.35 0.35 Synthesized Layered Magnesium 0.2 0.2 0.2 0.2 0.2 Silicate 0.2% Fluoride *10 Sodium Hydroxide Solution (50%) 0.54 0.54 0.54 0.54 0.54 *15 Tetrasodium Pyrophosphate *16 0 2.0 5.0 5.0 10.0 Flavor 0.80 0.80 0.75 0.75 0.75 Triclosan *22 0.28 Cetylpyridinium Chloride *23 0.045 Zinc Carbonate *24 1.0 Sodium Phytate 20% Solution * 19 25.0 17.5 5.0 2.5 0 Sodium Saccharin *20 0.25 0.25 0.25 0.25 0.25 Dyes 0.0008 0.0008 0.0008 0.0008 0.0008 Water QS to 100%
Definition of Components *1 Sodium Fluoride: NaF, available from Jinan Chemical Industry Co. Ltd.
*2 Sorbitol (70% sol.): Sorbitol 70% solution, available from Khalista (Liuzhou) Chemicals Industries Ltd.
*3 Glycerin: Glycerin, available from Asahi Denka *4 Polyethylene Glycol: PEG-300, available from Doe Chemical Company *5 Sodium Lauryl Sulfate (28% sol.): SLSS, available from Rhodia Specialty Chemical Wuxi Co. Ltd.
*6 Sodium Carboxymethyl Cellulose: CMC, available from Zhangjiagang city Sanhui Chemical Industry Co.,Ltd *7 Carbopol: Carbomer 956, available from Noveon, Inc.
*8 Xanthan Gum: KELDENT, available from CP Kelco Inc.
*9 Carrageenan: GELCARIN TP911 available from FMC Corporation food ingredients division *10 Synthesized Layered Magnesium Silicate 0.2% Fluoride: LAPONITE DF, available from Rockwood Additives Limited *11 Synthesized Layered Magnesium Silicate: LAPONITE D, available from Rockwood Additives Limited * 12 Amorphous Precipitated Silica: Zeodent 165, available from J. M. Huber Company *13 Fumed Silica: AEROSOL, available from Cabot & Degussa Corporation * 14 Mica, Titanium Dioxide Coated: available from Rona *15 Sodium Hydroxide Solution (50%): NaOH 50%, available from Guangzhou Chemical Company.
* 16 Tetrasodium Pyrophosphate: Sodium Pyrophosphate, Tetra (anhydrous), available from Lianyungang Duoling Fine Chemical Co. Ltd.
* 17 Sodium Phosphate, Monobasic, Monohydrate: MSP, available from Jiangsu Chengxing Phosphate Chemical Co. Ltd *18 Tribasic Sodium Phosphate: TSP, available from Jiangsu Jiangyin Phosph Chemicals *19 Sodium Phytate 20% Solution: available from Sichuan Chengdu Yason *20 Sodium Saccharin: available from Suzhou Fine Chemical *21 Stannous Fluoride: SnF2, available from Hashimoto *22 Triclosan: available from Ciba-Geigy Chemicals Ltd.
*23 Cetylpyridinium Chloride: available from Cambrex company *24 Zinc Carbonate: available from Bruggemann Chemical Method of Preparation The dentifrice compositions of Examples 1 - 10 may be made by any method known to one skilled in the art, and are suitably prepared as follows.
First, the hydrophilic clay material (component numbers 10-13) is dissolved in part of water in a container at room temperature, using Propeller Mixer mix until homogeneous. In a separate main mix pot, sorbitol solution (component number 2), glycerin (component number 3), polyethylene glycol (component number 4), sodium hydroxide solution (component number 15), dye and pigment (component number 14) as present in the composition, and remaining part of water, are mixed together with an agitator at 25 to 35rpm rotation speed at elevated temperature.
All remaining components except flavor and surfactant (component number 5) are added to main mix pot. The pot is hermetically closed, vacuum is built to around 100mmhg, homogenizer is turned at a rotation rate of 2400 to 3500rpm. The obtained mixture is further de-aerated.
To this is added the mixture made at first step. The obtained mixture is mixed and de-aerated. Finally, flavor and surfactant (component number 5) are added, the pot is again hermetically closed, mixed by homogenizer turned at a rotation rate of 2400 to 3500rpm for final homogenization, and de-aerated.
The obtained product is pumped out of the container and delivered to a primary packaging such as laminate tube.
The Example compositions herein have many benefits suitable for a dentifrice product.
All compositions provide lower abrasion to teeth surface, and are safer to teeth enamel compared to toothpastes containing abrasive material. All compositions provide soft mouth feel, and easier dispersion, and improved approach in the between-teeth area compared to toothpastes containing abrasive material. All compositions provide better consumer noticeability of flavor as compared to toothpastes containing abrasive material and the same level of the same flavor.
Further, all compositions can be manufactured at an economical cost. The compositions of Examples 1-5 provide anti-caries, anti-plaque, whitening, and anti-calculus benefit. The compositions of Examples 6-7 provide anti-caries, anti-plaque, whitening, anti-calculus, and anti-gingivitis benefit. The compositions of Examples 8-9 provide anti-caries, anti-plaque, whitening, anti-calculus, and anti-microbial benefit. The composition of Example 10 provides anti-caries, anti-plaque, and anti-calculus benefit.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm".
All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
available from 3V Company.
Natural gum derived anionic polymers are useful binder materials herein for effectively adding viscosity. Natural gum derived anionic polymers useful herein in clude carrageenan, xanthan gum, gellan gum, and locust bean gum. Particularly useful commercially available materials include xanthan gum by the tradename KELDENT series available from CP Kelco, and by the tradename RHODICARE series from Rhodia; gellan gum by the tradename KELCOGEL series from CP Kelco; and locust bean gum by the tradename GELLOID LB
series from FMC BioPolymer.
Also useful as binder material herein are starch and carrageenan. Carrageenan is commercially available by tradename VISCARI series and GELCARIN series from FMC
BioPolymer, by the tradename MEYPRO-SOL series from Meyhall AG, and by the tradename GENUVISCO series, GENU series and GENUTINE series from CP Kelco.
Additional Components The composition of the present invention may include other additional components, which may be selected by the artisan according to the desired characteristics of the final product and which are suitable for rendering the composition more cosmetically or aesthetically acceptable or to provide them with additional usage benefits. Such additional components generally are used individually at levels of no more than about 5% by weight of the composition.
Surfactants may be incorporated in the components of the present invention as an ingredient to aid in the thorough dispersion of the dentifrice throughout the oral cavity when applied thereto, as well as, to improve cosmetic acceptability and the foaming properties. The surfactants which can be included in the present composition include anionic, nonionic or amphoteric compounds, anionic compounds being preferred.
Suitable examples of anionic surfactants are higher alkyl sulfates such as potassium or sodium lauryl sulfate which is preferred, higher fatty acid monoglyceride monosulfates, such as the salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, alkyl sulfonates such as sodium dodecyl benzene sulfonate, higher fatty sulfoacetates, higher fatty acid esters of 1,2 dihydroxypropane sulfonate.
Examples of water soluble nonionic surfactants are condensation products of ethylene oxide with various hydrogen-containing compounds that are reactive therewith and have long hydrophobic chains (e.g., aliphatic chains of about 12 of 20 carbon atoms), which condensation products contain hydrophilic polyoxyethylene moieties, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides and other fatty moieties, and with propylene oxide and polypropylene oxides, e.g., Pluronic materials such as Pluronic F127.
The surfactant can be present in the present composition at a concentration of from about 0.5 to about 10.0% by weight, preferably about 1 to about 2% by weight.
Other ingredients which may be incorporated in the dentifrice composition of the present invention include pigments, dyes, flavoring and sweetening materials. For example, a striped product is obtained in accordance with the present invention wherein colorants of contrasting colors are incorporated in each of the components used in the practice of the present invention, the colorants being pharmacologically and physiologically nontoxic when used in the suggested amounts. Colorants used in the present invention include both pigments and dyes.
Pigments useful in the present invention include non-toxic, water insoluble inorganic pigments such as titanium dioxide and chromium oxide greens, ultramarine blues and pinks and ferric oxides as well as water insoluble dye lakes prepared by extending calcium or aluminum salts of FD&C dyes on alumina such as FD&C Green #1 lake, FD&C Blue #21ake, FD&C R&D
#30 lake, FD&C #5 Yellow and FD&C # Yellow 15 lake, The concentration of the dye in the present composition is no more than about 3% by weight. The pigments herein are distinguished from the abrasive materials, which the present composition is substantially free from, as pigments herein have a particle size in the range of from 100 to about 1000 microns, preferably from about 250 to about 500 microns. When present, the pigments are included in the present composition at from about 0.5% to about 3% by weight.
Any suitable flavoring or sweetening material may also be incorporated in the components of the present invention. Examples of suitable flavoring constituents are flavoring oils, e.g., oils of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon. Lemon, and orange, and methyl salicylate. Suitable sweetening agents include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, and sodium saccharin. Suitably, flavor and sweetening agents may together comprise from 0.01% to 5% by weight or more of the preparations.
Enzyme inhibitor, botanical extracts, natural herb extracts, and others may be included.
EXAMPLES
The following examples further describe and demonstrate the preferred embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration, and are not to be construed as liniitations of the present invention since many variations thereof are possible without departing from its spirit and scope.
The following dentifrice compositions are formed by the following components using the method of preparation described herein.
Compositions for Examples 1-5:
Component Ex.1 Ex.1 Ex.3 Ex. 4 Ex.5 Sodium Fluoride *1 0.243 0.243 0.243 0.243 0.243 Sorbitol (70% sol.) *2 39.299 39.299 25 20 Glycerin * 3 5 20 Polyethylene Glycol *4 10 Sodium Lauryl Sulfate (28% sol.) 5 7.5 1 7.5 10 *5 Sodium Carboxymethyl Cellulose 1.0 1.0 1 2.0 *6 Carbopol * 7 0.6 0.6 1.0 1.0 Xanthan Gum * 8 0.35 0.35 0.5 0.35 Carrageenan *9 0.5 Synthesized Layered Magnesium 1.0 1.0 0.4 0.5 Silicate 0.2% Fluoride *10 Synthesized Layered Magnesium 0.2 Silicate *11 Amorphous Precipitated Silica 0.5 *12 Fumed Silica *13 0.5 Mica, Titanium Dioxide Coated 0.5 *14 Sodium Hydroxide Solution 0.54 0.54 0.54 0.54 (50%) *15 Tetrasodium Pyrophosphate *16 0.05 0.05 0.05 0.05 Sodium Phosphate, Monobasic, 0.4 Monohydrate * 17 Tribasic Sodium Phosphate, NF 0.9 (Dodecahydrate) * 18 Flavor 0.80 0.80 0.50 0.80 1.00 Sodium Phytate 20% Solution * 19 5.0 2.5 25.0 2.5 1.25 Sodium Saccharin *20 0.25 0.25 0.25 0.25 0.25 Dyes 0.0008 0.0008 0.0008 0.0008 0.0008 Deionized Water QS to 100%
Compositions for Examples 6-10 Component Ex. 6 Ex. 7 Ex.8 Ex. 9 Ex. 10 Sodium Fluoride *1 0.243 0.243 0.243 Stannous Fluoride *21 0.454 0.454 Sorbitol (70% sol.) *2 39.299 39.299 39.299 39.299 39.299 Sodium Lauryl Sulfate (28% sol.) *5 1 3 5 7.5 10 Sodium Carboxymethyl Cellulose *6 2.0 2.0 1.0 1.0 1.0 Carbopol *7 0.6 0.6 0.6 Xanthan Gum *8 0.35 0.35 0.35 0.35 0.35 Synthesized Layered Magnesium 0.2 0.2 0.2 0.2 0.2 Silicate 0.2% Fluoride *10 Sodium Hydroxide Solution (50%) 0.54 0.54 0.54 0.54 0.54 *15 Tetrasodium Pyrophosphate *16 0 2.0 5.0 5.0 10.0 Flavor 0.80 0.80 0.75 0.75 0.75 Triclosan *22 0.28 Cetylpyridinium Chloride *23 0.045 Zinc Carbonate *24 1.0 Sodium Phytate 20% Solution * 19 25.0 17.5 5.0 2.5 0 Sodium Saccharin *20 0.25 0.25 0.25 0.25 0.25 Dyes 0.0008 0.0008 0.0008 0.0008 0.0008 Water QS to 100%
Definition of Components *1 Sodium Fluoride: NaF, available from Jinan Chemical Industry Co. Ltd.
*2 Sorbitol (70% sol.): Sorbitol 70% solution, available from Khalista (Liuzhou) Chemicals Industries Ltd.
*3 Glycerin: Glycerin, available from Asahi Denka *4 Polyethylene Glycol: PEG-300, available from Doe Chemical Company *5 Sodium Lauryl Sulfate (28% sol.): SLSS, available from Rhodia Specialty Chemical Wuxi Co. Ltd.
*6 Sodium Carboxymethyl Cellulose: CMC, available from Zhangjiagang city Sanhui Chemical Industry Co.,Ltd *7 Carbopol: Carbomer 956, available from Noveon, Inc.
*8 Xanthan Gum: KELDENT, available from CP Kelco Inc.
*9 Carrageenan: GELCARIN TP911 available from FMC Corporation food ingredients division *10 Synthesized Layered Magnesium Silicate 0.2% Fluoride: LAPONITE DF, available from Rockwood Additives Limited *11 Synthesized Layered Magnesium Silicate: LAPONITE D, available from Rockwood Additives Limited * 12 Amorphous Precipitated Silica: Zeodent 165, available from J. M. Huber Company *13 Fumed Silica: AEROSOL, available from Cabot & Degussa Corporation * 14 Mica, Titanium Dioxide Coated: available from Rona *15 Sodium Hydroxide Solution (50%): NaOH 50%, available from Guangzhou Chemical Company.
* 16 Tetrasodium Pyrophosphate: Sodium Pyrophosphate, Tetra (anhydrous), available from Lianyungang Duoling Fine Chemical Co. Ltd.
* 17 Sodium Phosphate, Monobasic, Monohydrate: MSP, available from Jiangsu Chengxing Phosphate Chemical Co. Ltd *18 Tribasic Sodium Phosphate: TSP, available from Jiangsu Jiangyin Phosph Chemicals *19 Sodium Phytate 20% Solution: available from Sichuan Chengdu Yason *20 Sodium Saccharin: available from Suzhou Fine Chemical *21 Stannous Fluoride: SnF2, available from Hashimoto *22 Triclosan: available from Ciba-Geigy Chemicals Ltd.
*23 Cetylpyridinium Chloride: available from Cambrex company *24 Zinc Carbonate: available from Bruggemann Chemical Method of Preparation The dentifrice compositions of Examples 1 - 10 may be made by any method known to one skilled in the art, and are suitably prepared as follows.
First, the hydrophilic clay material (component numbers 10-13) is dissolved in part of water in a container at room temperature, using Propeller Mixer mix until homogeneous. In a separate main mix pot, sorbitol solution (component number 2), glycerin (component number 3), polyethylene glycol (component number 4), sodium hydroxide solution (component number 15), dye and pigment (component number 14) as present in the composition, and remaining part of water, are mixed together with an agitator at 25 to 35rpm rotation speed at elevated temperature.
All remaining components except flavor and surfactant (component number 5) are added to main mix pot. The pot is hermetically closed, vacuum is built to around 100mmhg, homogenizer is turned at a rotation rate of 2400 to 3500rpm. The obtained mixture is further de-aerated.
To this is added the mixture made at first step. The obtained mixture is mixed and de-aerated. Finally, flavor and surfactant (component number 5) are added, the pot is again hermetically closed, mixed by homogenizer turned at a rotation rate of 2400 to 3500rpm for final homogenization, and de-aerated.
The obtained product is pumped out of the container and delivered to a primary packaging such as laminate tube.
The Example compositions herein have many benefits suitable for a dentifrice product.
All compositions provide lower abrasion to teeth surface, and are safer to teeth enamel compared to toothpastes containing abrasive material. All compositions provide soft mouth feel, and easier dispersion, and improved approach in the between-teeth area compared to toothpastes containing abrasive material. All compositions provide better consumer noticeability of flavor as compared to toothpastes containing abrasive material and the same level of the same flavor.
Further, all compositions can be manufactured at an economical cost. The compositions of Examples 1-5 provide anti-caries, anti-plaque, whitening, and anti-calculus benefit. The compositions of Examples 6-7 provide anti-caries, anti-plaque, whitening, anti-calculus, and anti-gingivitis benefit. The compositions of Examples 8-9 provide anti-caries, anti-plaque, whitening, anti-calculus, and anti-microbial benefit. The composition of Example 10 provides anti-caries, anti-plaque, and anti-calculus benefit.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm".
All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (13)
1. A dentifrice composition comprising:
(a) a hydrophilic clay material;
(b) a phytic acid compound;
(c) an effective amount of an oral care active; and (d) a polar solvent carrier;
wherein the composition is substantially free of abrasive material.
(a) a hydrophilic clay material;
(b) a phytic acid compound;
(c) an effective amount of an oral care active; and (d) a polar solvent carrier;
wherein the composition is substantially free of abrasive material.
2. The dentifrice composition of Claim 1 comprising:
(a) from about 0.1% to about 10% of the hydrophilic clay material; and (b) from about 0.01 % to about 20% of the phytic acid compound.
(a) from about 0.1% to about 10% of the hydrophilic clay material; and (b) from about 0.01 % to about 20% of the phytic acid compound.
3. The dentifrice composition of Claim 1 wherein the hydrophilic clay material is selected from the group consisting of a natural and synthesized layered silicate minerals, fumed silicas, thickening precipitated silica, and mixtures thereof.
4. The dentifrice composition of Claim 3 wherein the hydrophilic clay material is a synthesized layered magnesium silicate.
5. The dentifrice composition of Claim 1 further comprising an additional binder material selected from the group consisting of modified cellulose polymers, carboxyvinyl polymers, natural gum derived anionic polymers, and mixtures thereof.
6. The dentifrice composition of Claim 1 wherein the oral care active is selected from the group consisting of anti-calculus agents, stannous ion sources, fluoride ion sources, whitening agents, anti-microbial agents, anti-plaque agents, anti-inflammatory agents, nutrients, antioxidants, anti-viral agents, analgesic and anesthetic agents, zinc-containing layered material, and mixtures thereof.
7. The dentifrice composition of Claim 6 wherein the oral care active is selected from the group consisting of fluoride ion sources, stannous ion sources, pyrophosphate salts, polyphosphate salts, hydrogen peroxide, triclosan, and mixtures thereof.
8. The dentifrice composition of Claim 6 wherein the oral care active is an anti-cavity active selected from the group consisting of cetylpyridinium chloride, stannous ion sources, and mixtures thereof.
9. The dentifrice composition of Claim 6 wherein the oral care active is a zinc-containing layered material having a relative zinc lability of greater than about 25%.
10. The dentifrice composition of Claim 9 wherein the zinc-containing layered material is selected from the group consisting of basic zinc carbonate, zinc carbonate hydroxide, zinc copper carbonate hydroxide, aurichalcite, copper zinc carbonate hydroxide, rosasite, phyllosilicate containing zinc ions, layered double hydroxide, hydroxyl double salts, and mixtures thereof.
11. The dentifrice composition of Claim 9 wherein the zinc-containing layered material is basic zinc carbonate.
12. The dentifrice composition of Claim 1 wherein the polar solvent carrier comprises, by weight of the entire composition, from about 30% to about 95% water.
13. A method of cleaning teeth absent the use of abrasive material comprising the step of brushing the teeth with the dentifrice composition of Claim 1.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74053805P | 2005-11-29 | 2005-11-29 | |
US60/740,538 | 2005-11-29 | ||
US75140505P | 2005-12-16 | 2005-12-16 | |
US60/751,405 | 2005-12-16 | ||
US11/545,266 US20070122357A1 (en) | 2005-11-29 | 2006-10-10 | Dentifrice composition |
US11/545,266 | 2006-10-10 | ||
PCT/IB2006/054510 WO2007063506A2 (en) | 2005-11-29 | 2006-11-29 | Dentifrice composition free of abrasive material |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2631537A1 true CA2631537A1 (en) | 2007-06-07 |
Family
ID=38007033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002631537A Abandoned CA2631537A1 (en) | 2005-11-29 | 2006-11-29 | Dentifrice composition free of abrasive material |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1954238A2 (en) |
JP (1) | JP2009513695A (en) |
KR (1) | KR20080063528A (en) |
AU (1) | AU2006321206A1 (en) |
BR (1) | BRPI0619387A2 (en) |
CA (1) | CA2631537A1 (en) |
WO (1) | WO2007063506A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009520829A (en) * | 2005-12-20 | 2009-05-28 | ザ プロクター アンド ギャンブル カンパニー | Oral care composition comprising zinc and phytate |
WO2010058522A1 (en) * | 2008-11-19 | 2010-05-27 | 花王株式会社 | Method for removing solid product formed on surfaces of teeth |
JP5563212B2 (en) * | 2008-11-19 | 2014-07-30 | 花王株式会社 | Oral composition |
JP5563226B2 (en) * | 2008-11-19 | 2014-07-30 | 花王株式会社 | Composition for removing solid product formed on tooth surface |
CN102215813B (en) | 2008-11-19 | 2014-01-08 | 花王株式会社 | Method for removing solid product formed on surfaces of teeth |
WO2012060837A1 (en) * | 2010-11-04 | 2012-05-10 | Colgate-Palmolive Company | Dentifrice composition with reduced astringency |
JP5625818B2 (en) * | 2010-11-30 | 2014-11-19 | ライオン株式会社 | Dentifrice composition |
JP5097841B2 (en) | 2011-04-08 | 2012-12-12 | 花王株式会社 | Oral composition |
JP2012240966A (en) * | 2011-05-19 | 2012-12-10 | Lion Corp | Organic-inorganic composite thickened body and method for preparing the same, and gel cosmetic or substrate for external preparation |
EP2713990B1 (en) | 2011-06-02 | 2018-03-21 | Colgate-Palmolive Company | Low water metal ion dentifrice |
BR112015015136B1 (en) | 2012-12-27 | 2020-02-27 | Unilever Nv | DENTAL PASTE COMPOSITION, ORAL HYGIENE PROMOTION METHOD AND NON-THERAPEUTIC USE OF A DENTAL PASTE COMPOSITION |
JP5765407B2 (en) * | 2013-11-28 | 2015-08-19 | ライオン株式会社 | Dentifrice composition |
CN112739351A (en) * | 2018-09-18 | 2021-04-30 | 因诺西特克股份公司 | Calcium oxalate crystallization inhibitors for renal disorders |
JP2020100596A (en) * | 2018-12-25 | 2020-07-02 | ライオン株式会社 | Oral biofilm remover and oral composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4528181A (en) * | 1984-02-01 | 1985-07-09 | Colgate-Palmolive Company | Dentifrice containing dual sources of fluoride |
GB0016067D0 (en) * | 2000-06-30 | 2000-08-23 | Procter & Gamble | Oral compositions |
US8491877B2 (en) * | 2003-03-18 | 2013-07-23 | The Procter & Gamble Company | Composition comprising zinc-containing layered material with a high relative zinc lability |
-
2006
- 2006-11-29 BR BRPI0619387-0A patent/BRPI0619387A2/en not_active IP Right Cessation
- 2006-11-29 WO PCT/IB2006/054510 patent/WO2007063506A2/en active Application Filing
- 2006-11-29 KR KR1020087012805A patent/KR20080063528A/en not_active Application Discontinuation
- 2006-11-29 EP EP06832005A patent/EP1954238A2/en not_active Withdrawn
- 2006-11-29 CA CA002631537A patent/CA2631537A1/en not_active Abandoned
- 2006-11-29 JP JP2008538490A patent/JP2009513695A/en not_active Withdrawn
- 2006-11-29 AU AU2006321206A patent/AU2006321206A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2009513695A (en) | 2009-04-02 |
WO2007063506A3 (en) | 2007-10-11 |
KR20080063528A (en) | 2008-07-04 |
AU2006321206A1 (en) | 2007-06-07 |
WO2007063506A2 (en) | 2007-06-07 |
EP1954238A2 (en) | 2008-08-13 |
BRPI0619387A2 (en) | 2011-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2631254A1 (en) | Dentifrice composition comprising binder system comprising hydrophilic clay material | |
US20070122359A1 (en) | Dentifrice composition comprising binder system comprising hydrophilic clay material | |
CA2631537A1 (en) | Dentifrice composition free of abrasive material | |
US20070122358A1 (en) | Dentifrice composition free of abrasive material | |
AU2005316919B2 (en) | Oral compositions containing extracts of Rosmarinus and related methods | |
CA2822402C (en) | Films and compositions comprising the same | |
KR101019873B1 (en) | Dentifrice composition | |
CA2927619C (en) | Anti-malodor oral care composition containing arginine and zinc | |
US20060140882A1 (en) | Two phase whitening oral care composition | |
CN101316571A (en) | Dentifrice composition free of abrasive material | |
US20050207997A1 (en) | Dual component dentifrices and methods of whitening using the same | |
MX2008006887A (en) | Dentifrice composition free of abrasive material | |
KR20060060291A (en) | Toothpaste composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |